California
|
87-0673375
|
|
(State of Incorporation)
|
(I.R.S. Employer Identification No.)
|
6720 N. Scottsdale Road, Suite # 390 Scottsdale, AZ
|
85253
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☐
|
Smaller reporting company ☒
|
PART I
|
Page
|
||
Item 1.
|
4
|
||
Item 1A.
|
13
|
||
Item 1B.
|
20
|
||
Item 2.
|
21
|
||
Item 3.
|
21
|
||
Item 4.
|
22
|
||
PART II
|
|||
Item 5.
|
23
|
||
Item 6.
|
23
|
||
Item 7.
|
23
|
||
Item 7A.
|
31
|
||
Item 8.
|
31
|
||
Item 9.
|
62
|
||
Item 9A.
|
62
|
||
Item 9B.
|
63
|
||
PART III
|
|||
Item 10.
|
63
|
||
Item 11.
|
63
|
||
Item 12.
|
63
|
||
Item 13.
|
63
|
||
Item 14.
|
63
|
||
PART IV
|
|||
Item 15.
|
63
|
Fat (oil)
|
18-23%
|
Protein
|
12-16%
|
Total Dietary Fiber
|
20-30%
|
Moisture
|
4-8%
|
Ash
|
6-14%
|
Calories
|
3.2 kcal/gram
|
1. | Emphasis on Natural, Organic and Functional Foods: Based on industry sources, the U.S. market for natural, organic and functional foods grew in excess of 10% and exceeded $110 billion in 2014 making that category 15% of total U.S. food sales, with natural and organic sub-sectors of that market growing 12% and 13% respectively – the fastest growing segments in the U.S. market for foods. These sales levels and growth rates are much higher than previously forecast confirming that the trend to healthy eating as part of an overall wellness regimen is not a fad. Our portfolio of functional ingredients includes rice bran extracts that demonstrate beneficial properties in areas of cardiovascular health, weight management, glucose balance, inflammatory response and gastrointestinal health. Premium ingredient manufacturers are in high demand and we are strategically positioned to take advantage of this growing and sustainable market opportunity. We will continue marketing our proprietary and patented ingredients directly to formulators and co-packers who manufacture turnkey finished products for direct to consumer marketing companies (i.e., multi-level marketing (MLM), web, radio, retail) and to active ingredient distributors to reduce new product development cycles and drive sales of our functional ingredients. We believe that focusing our marketing efforts on distributors to reduce new product development cycles and drive sales of our functional ingredients. We believe that focusing our marketing efforts on distributors, formulators and co-packaging companies will increase sales of our Stage II products in both the short- and long-term as new functional ingredients are added to our portfolio of products. |
2. | Acquisition of formulating and packaging company that serves the Natural, Organic and Functional Food market: In January 2014 we acquired HN. By incorporating HN’s formulating and packaging capabilities into our business model, we expect to drive sales of our Stage II products into multiple natural, organic and functional food channels allowing us to capture not only single ingredient sales but also sales of blended finished products consisting predominantly of our ingredients blended with other products and sold as a finished product on a business to business basis. In 2014 and 2015 we used capital raised from the market to double the capacity of HN. As a part of our strategy to grow our natural organic and functional food business, we will continue to develop functional ingredients and packaged, compounded finished products from rice bran and to validate their functionality through evidence-based scientific studies and human clinical trials. |
3. | Increased production capacity of our Stage II products; Addition of proprietary and patent pending protein products: During 2014, we doubled our capacity to produce certain Stage II products at our Dillon, Montana facility in response to projected increased demand for natural, organic and functional food products. We completed the expansion project near the end of 2014. We co-developed proprietary and provisionally patented technologies with DSM Innovation Center, a subsidiary of Royal DSM N.V. that enables the extraction of protein from DRB and SRB. In early 2015 we launched new protein products from our U.S. operations and plan to produce protein from DRB in our Brazil segment in the future based on the technologies developed with DSM. In addition, we entered into a series of agreements with various affiliates of Wilmar International limited (collectively, Wilmar) to develop and commercialize rice bran products, including protein, for the China market. |
4. | Increasing global demand for vegetable oil: Our Brazil segment currently sells all of the rice bran oil it can produce in our oil extraction and bio-refining plant in Pelotas, Brazil. Following the capital expansion project at this plant, raw rice bran processing capacity increased approximately 50% in first quarter 2015. That expansion increased raw rice bran processing capacity from 200 metric tons per day to over 300 metric tons per day. |
5. | Demand for minimally processed, natural, non-genetically modified “clean” label food products: The market for natural, organic and functional foods is rapidly expanding in the U.S., Europe and other global markets with increasing demand for healthy, natural and minimally processed ingredients that are hypoallergenic, non-genetically modified and produced in a sustainable fashion. The regulatory need to add front-of-label warnings on food items is driving food companies to replace standard food ingredients like soy and wheat with “cleaner” ingredients such as rice bran which is non-allergenic, non-genetically modified, natural and minimally processed. Incorporation of our food ingredients by major global food companies continue as more food companies adopt rice bran as a standard food ingredient. This trend is not limited to human foods as we are finding a similar transition to “clean” ingredients among high-end animal nutrition companies. |
6. | The value of proprietary, evidence-based functional ingredients for nutraceuticals and functional foods: With increasing medical costs associated with doctor visits and medications, consumers are becoming more proactive in adopting and maintaining healthier lifestyles through exercise, balanced nutrition and increased consumption of functional foods and nutraceuticals. Associated with this trend is higher demand by marketers of nutraceuticals and functional foods for novel functional ingredients and particularly for proprietary and patented ingredients that provide barriers to competition in the marketplace, therefore commanding higher premiums. We currently develop and commercialize proprietary rice bran ingredients and derivatives from our Stage II facility in the USA segment. |
7. | Increase global distribution network: Our growth strategy includes increasing sales of our products in overseas markets. In 2015 we added distributors in Canada and Mexico and plan to strengthen our network in other global markets. |
8. | Continue to generate evidence-based functionality of our proprietary ingredients: |
● | A 57-subject clinical trial conducted by Advanced Medical Research (Journal of Nutritional Biochemistry, Volume 13, 2002), with our funding, suggested that consumption of our RiSolubles nutritional supplements may lower blood glucose levels of type 1 and type 2 diabetes mellitus patients and may be beneficial in reducing high blood cholesterol and high blood lipid levels. To date, we have not developed any such products nor sanctioned any subsequent trials to confirm the results from the initial trial. If warranted, we may develop products which address the use of SRB products as medical foods for, and to potentially make health benefit claims relating to, the effects of dietary rice bran on overall health and well-being and as it may relate to maintaining balanced sugar and lipid levels. |
● | We have maintained relationships with several medical institutions and practicing physicians who may continue to conduct clinical trials and beta work for our products. Some of these previous clinical trials are reviewed in an article entitled “Effects of Stabilized Rice Bran, its Soluble and Fiber Fractions on Blood Glucose Levels and Serum Lipid Parameters in Humans with Diabetes Mellitus Types I and II” published in the Journal of Nutritional Biochemistry (March 2002, 175-187). The trial produced positive results by showing that the levels of blood lipids and glycosylated hemoglobin were reduced. Subsequently, three domestic and six international patents were issued to us on the strength of this clinical trial. |
● | In December 2007, we formed Rice Science, LLC (Rice Science), and a Delaware limited liability company, with Herbal Science Singapore Pte. Ltd. (Herbal Science) to develop nutraceutical extracts and pharmaceutical chemistries from our SRB. Herbal Science utilized sophisticated methodologies in the identification and isolation of specific biologically active compounds that have been tested for effectiveness against specific disease conditions. In March 2011, our partnership with Herbal Science ended with us acquiring the membership interest formerly owned by Herbal Science, leaving Rice Science as our wholly owned subsidiary. We are hopeful that the research performed by Herbal Science will result in biologically active SRB extracts for use in the nutraceutical and functional food industry.In 2008, Rice Science conducted research regarding the development of extracts from SRB that would be effective in addressing inflammation and pain. A number of SRB extracts have been tested with two identified as having significant in vitro activities. A blend of these two extracts was created to produce a third extract that exhibits a high level of in vitro inhibition of Cox 1, Cox 2 and Lox 5 enzymes (Journal of Medicinal Food (2009) 12, 615-623). This extract was used in a pharmacokinetic study to determine uptake kinetics of key bioactives into human serum. Results indicated that the bioactive compounds were rapidly assimilated. The next step would be to conduct a human clinical trial if funds were available. A number of active compounds were identified and modeled. |
● | Late in 2007, the Cancer Biomarkers Group in the Department of Cancer Studies and Molecular Medicine, University of Leicester in Leicester, UK published a research paper evaluating the effect of our SRB in ApcMin mice (British Journal of Cancer (2007) 96, 248-254). The mice were genetically modified to serve as models for mammary, prostate and intestinal carcinogenesis. They reported that consumption of SRB (30% in the diet) reduced the numbers of intestinal adenomas in these mice by 51% compared to the same mice on a control diet. |
• | problems combining the purchased operations, technologies or products; |
• | unanticipated costs; |
• | diversion of management’s attention from our core business; |
• | adverse effects on existing business relationships with suppliers and customers; |
• | risks associated with entering markets in which we have no or limited prior experience; |
• | potential loss of key employees of purchased organizations; |
• | problems combining the purchased operations, technologies or products; |
• | unanticipated costs; |
• | diversion of management’s attention from our core business; |
• | adverse effects on existing business relationships with suppliers and customers; |
• | risks associated with entering markets in which we have no or limited prior experience; and |
• | potential loss of key employees of purchased organizations. |
• | cultural differences in the conduct of business; |
• | fluctuations in foreign exchange rates; |
• | greater difficulty in accounts receivable collection and longer collection periods; |
• | challenges in obtaining and maintaining financing; |
• | impact of recessions in economies outside of the United States; |
• | reduced or obtainable protection for intellectual property rights in some countries; |
• | unexpected changes in regulatory requirements; |
• | tariffs and other trade barriers; |
• | political conditions in each country; |
• | management and operation of an enterprise spread over various countries; |
• | the burden and administrative costs of complying with a wide variety of foreign laws; and |
• | currency restrictions. |
• | exchange rate movements; |
• | exchange control policies; |
• | expansion or contraction of the Brazilian economy, as measured by rates of growth in GDP; |
• | inflation; |
• | tax policies; |
• | other economic political, diplomatic and social developments in or affecting Brazil; |
• | interest rates; |
• | energy shortages; |
• | liquidity of domestic capital and lending markets; |
• | changes in environmental regulation; and |
• | social and political instability. |
• | announcements of new products or product enhancements by us or our competitors; |
• | fluctuations in our quarterly or annual operating results; |
• | developments in our relationships with customers and suppliers; |
• | our ability to obtain financing; |
• | the loss of services of one or more of our executive officers or other key employees; |
• | announcements of technological innovations or new systems or enhancements used by us or our competitors; |
• | developments in our or our competitors’ intellectual property rights; |
• | adverse effects to our operating results due to impairment of goodwill; |
• | failure to meet the expectation of securities analysts’ or the public; |
• | general economic and market conditions; |
• | our ability to expand our operations, domestically and internationally; |
• | the amount and timing of expenditures related to any expansion; |
• | litigation involving us, our industry or both; |
• | actual or anticipated changes in expectations by investors or analysts regarding our performance; and |
• | price and volume fluctuations in the overall stock market from time to time. |
Primary Segment
|
Location
|
Status
|
Primary Use
|
|||
USA
|
West Sacramento, California
|
Leased
|
Warehousing, and administrative
|
|||
USA
|
Mermentau, Louisiana
|
Owned
|
Manufacturing
|
|||
USA
|
Lake Charles, Louisiana
|
Building – owned
|
Warehouse
|
|||
Land - leased
|
||||||
USA
|
Dillon, Montana
|
Owned
|
Manufacturing
|
|||
USA
|
Irving, Texas
|
Leased
|
Manufacturing, warehousing and distribution
|
|||
Brazil
|
Pelotas, Brazil
|
Owned
|
Manufacturing, R&D and administrative
|
|||
Corporate
|
Scottsdale, Arizona
|
Leased
|
Administrative – corporate offices
|
Low
|
High
|
|||||||
2015
|
||||||||
Fourth Quarter
|
$
|
1.70
|
$
|
2.40
|
||||
Third Quarter
|
2.07
|
3.44
|
||||||
Second Quarter
|
3.14
|
4.25
|
||||||
First Quarter
|
2.50
|
4.67
|
||||||
2014
|
||||||||
Fourth Quarter
|
$
|
3.74
|
$
|
5.31
|
||||
Third Quarter
|
4.28
|
6.90
|
||||||
Second Quarter
|
3.56
|
7.45
|
||||||
First Quarter
|
4.05
|
6.95
|
2015
|
% of
Total
Revenues
|
2014
|
% of
Total
Revenues
|
Change
|
% Change
|
|||||||||||||||||||
USA segment
|
$
|
23,341
|
58.5
|
$
|
23,096
|
57.6
|
$
|
245
|
1.1
|
|||||||||||||||
Brazil segment
|
16,601
|
41.6
|
17,012
|
42.4
|
(411
|
)
|
(2.4
|
)
|
||||||||||||||||
Intersegment
|
(46
|
)
|
(0.1
|
)
|
-
|
-
|
(46
|
)
|
NA
|
|||||||||||||||
Total revenues
|
$
|
39,896
|
100.0
|
$
|
40,108
|
100.0
|
$
|
(212
|
)
|
(0.5
|
)
|
2015
|
Gross
Profit %
|
2014
|
Gross
Profit %
|
Change
|
Change
in Gross
Profit %
|
|||||||||||||||||||
USA segment
|
$
|
7,418
|
31.8
|
$
|
6,972
|
30.2
|
$
|
446
|
1.6
|
|||||||||||||||
Brazil segment
|
652
|
3.9
|
(2,503
|
)
|
(14.7
|
)
|
3,155
|
18.6
|
||||||||||||||||
Total gross profit
|
$
|
8,070
|
20.1
|
$
|
4,469
|
11.1
|
$
|
3,601
|
9.0
|
|
2015
|
|||||||||||||||
|
Corporate
|
USA
|
Brazil
|
Consolidated
|
||||||||||||
Selling, general and administrative
|
$
|
4,892
|
$
|
4,288
|
$
|
3,387
|
$
|
12,567
|
||||||||
Depreciation and amortization
|
79
|
1,569
|
131
|
1,779
|
||||||||||||
Total operating expenses
|
$
|
4,971
|
$
|
5,857
|
$
|
3,518
|
$
|
14,346
|
|
2014
|
|||||||||||||||
|
Corporate
|
USA
|
Brazil
|
Consolidated
|
||||||||||||
Selling, general and administrative
|
$
|
5,941
|
$
|
4,133
|
$
|
4,280
|
$
|
14,354
|
||||||||
Depreciation and amortization
|
52
|
2,137
|
690
|
2,879
|
||||||||||||
Total operating expenses
|
$
|
5,993
|
$
|
6,270
|
$
|
4,970
|
$
|
17,233
|
|
Favorable (Unfavorable) Change
|
|||||||||||||||
|
Corporate
|
USA
|
Brazil
|
Consolidated
|
||||||||||||
Selling, general and administrative
|
$
|
1,049
|
$
|
(155
|
)
|
$
|
893
|
$
|
1,787
|
|||||||
Depreciation and amortization
|
(27
|
)
|
568
|
559
|
1,100
|
|||||||||||
Total operating expenses
|
$
|
1,022
|
$
|
413
|
$
|
1,452
|
$
|
2,887
|
● | USA segment depreciation and amortization expense decreased $0.6 million due to incremental declines in amortization expense of intangible assets associated with the acquisition of HN in 2014. |
● | Brazil segment depreciation and amortization expense decreased $0.6 million due to intangible assets becoming fully amortized in 2015. |
|
2015
|
|||||||||||||||
|
Corporate
|
USA
|
Brazil
|
Consolidated
|
||||||||||||
Interest income
|
$
|
-
|
$
|
-
|
$
|
107
|
107
|
|||||||||
Interest expense
|
(1,404
|
)
|
-
|
(1,697
|
)
|
(3,101
|
)
|
|||||||||
Change in fair value of derivative warrant and conversion liabilities
|
1,001
|
-
|
-
|
1,001
|
||||||||||||
Financing expense
|
-
|
-
|
-
|
-
|
||||||||||||
Loss on extinguishment
|
(1,904
|
)
|
-
|
-
|
(1,904
|
)
|
||||||||||
Foreign currency exchange, net
|
-
|
-
|
(370
|
)
|
(370
|
)
|
||||||||||
Other
|
154
|
-
|
(363
|
)
|
(209
|
)
|
||||||||||
Other income (expense)
|
$
|
(2,153
|
)
|
$
|
-
|
$
|
(2,323
|
)
|
$
|
(4,476
|
)
|
|
2014
|
|||||||||||||||
|
Corporate
|
USA
|
Brazil
|
Consolidated
|
||||||||||||
Interest income
|
$
|
-
|
$
|
-
|
$
|
115
|
115
|
|||||||||
Interest expense
|
(7,949
|
)
|
-
|
(2,385
|
)
|
(10,334
|
)
|
|||||||||
Change in fair value of derivative warrant and conversion liabilities
|
(1,209
|
)
|
-
|
-
|
(1,209
|
)
|
||||||||||
Financing expense
|
(2,072
|
)
|
-
|
-
|
(2,072
|
)
|
||||||||||
Loss on extinguishment
|
(906
|
)
|
-
|
-
|
(906
|
)
|
||||||||||
Foreign currency exchange, net
|
-
|
-
|
(174
|
)
|
(174
|
)
|
||||||||||
Other
|
-
|
-
|
(587
|
)
|
(587
|
)
|
||||||||||
Other income (expense)
|
$
|
(12,136
|
)
|
$
|
-
|
$
|
(3,031
|
)
|
$
|
(15,167
|
)
|
|
Favorable (Unfavorable) Change
|
|||||||||||||||
|
Corporate
|
USA
|
Brazil
|
Consolidated
|
||||||||||||
Interest income
|
$
|
-
|
$
|
-
|
$
|
(8
|
)
|
$
|
(8
|
)
|
||||||
Interest expense
|
6,545
|
-
|
688
|
7,233
|
||||||||||||
Change in fair value of derivative warrant and conversion liabilities
|
2,210
|
-
|
-
|
2,210
|
||||||||||||
Financing expense
|
2,072
|
-
|
-
|
2,072
|
||||||||||||
Loss on extinguishment
|
(998
|
)
|
-
|
-
|
(998
|
)
|
||||||||||
Foreign currency exchange, net
|
-
|
-
|
(196
|
)-
|
(196
|
)
|
||||||||||
Other
|
154
|
-
|
224
|
378
|
||||||||||||
Other income (expense)
|
$
|
9,983
|
$
|
-
|
$
|
708
|
$
|
10,691
|
2015
|
||||||||||||
Corporate
and USA
|
Brazil
|
Consolidated
|
||||||||||
Net loss
|
$
|
(5,387
|
)
|
$
|
(5,189
|
)
|
$
|
(10,576
|
)
|
|||
Adjustments to reconcile net loss to net cash used in operations:
|
||||||||||||
Depreciation and amortization
|
2,538
|
1,525
|
4,063
|
|||||||||
Change in fair value of derivative warrant and conversion liabilities
|
(1,001
|
)
|
-
|
(1,001
|
)
|
|||||||
Loss on extinguishment
|
1,904
|
-
|
1,904
|
|||||||||
Interest accreted
|
455
|
-
|
455
|
|||||||||
Other adjustments, net
|
799
|
167
|
966
|
|||||||||
Changes in operating asset and liabilities:
|
(1,245
|
)
|
1,640
|
395
|
||||||||
Net cash used in operating activities
|
$
|
(1,937
|
)
|
$
|
(1,857
|
)
|
$
|
(3,794
|
)
|
2014
|
||||||||||||
Corporate
and USA
|
Brazil
|
Consolidated
|
||||||||||
Net loss
|
$
|
(16,123
|
)
|
$
|
(10,504
|
)
|
$
|
(26,627
|
)
|
|||
Adjustments to reconcile net loss to net cash used in operations:
|
||||||||||||
Depreciation and amortization
|
3,211
|
3,338
|
6,549
|
|||||||||
Change in fair value of derivative warrant and conversion liabilities
|
1,209
|
-
|
1,209
|
|||||||||
Loss on extinguishment
|
906
|
-
|
906
|
|||||||||
Financing expense
|
2,072
|
-
|
2,072
|
|||||||||
Interest accreted
|
7,058
|
-
|
7,058
|
|||||||||
Other adjustments, net
|
(441
|
)
|
286
|
(155
|
)
|
|||||||
Changes in operating asset and liabilities:
|
(797
|
)
|
(282
|
)
|
(1,079
|
)
|
||||||
Net cash used in operating activities
|
$
|
(2,905
|
)
|
$
|
(7,162
|
)
|
$
|
(10,067
|
)
|
2015
|
2014
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
1,070
|
$
|
3,610
|
||||
Restricted cash
|
1,921
|
1,920
|
||||||
Accounts receivable, net of allowance for doubtful accounts of $512 and $574 (variable interest entity restricted $1,003 and $1,980)
|
2,169
|
3,055
|
||||||
Inventories
|
3,857
|
3,508
|
||||||
Operating taxes recoverable
|
809
|
737
|
||||||
Deposits and other current assets
|
895
|
1,071
|
||||||
Total current assets
|
10,721
|
13,901
|
||||||
Property, net (variable interest entity restricted $2,102 and $3,727)
|
18,328
|
24,753
|
||||||
Goodwill
|
3,258
|
4,431
|
||||||
Intangible assets, net
|
1,225
|
2,740
|
||||||
Other long-term assets
|
103
|
88
|
||||||
Total assets
|
$
|
33,635
|
$
|
45,913
|
||||
LIABILITIES, TEMPORARY EQUITY AND EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
2,514
|
$
|
3,286
|
||||
Accrued salary, wages and benefits
|
2,325
|
2,206
|
||||||
Accrued expenses
|
4,789
|
4,830
|
||||||
Current maturities of debt (variable interest entity nonrecourse $2,750 and $4,758)
|
5,050
|
4,808
|
||||||
Total current liabilities
|
14,678
|
15,130
|
||||||
Long-term debt, less current portion (variable interest entity nonrecourse $3,553 and $6,203)
|
10,908
|
11,288
|
||||||
Derivative warrant liabilities
|
678
|
955
|
||||||
Deferred tax liability
|
34
|
225
|
||||||
Total liabilities
|
26,298
|
27,598
|
||||||
Commitments and contingencies
|
||||||||
Temporary Equity - Redeemable noncontrolling interest in Nutra SA
|
69
|
2,643
|
||||||
Equity:
|
||||||||
Equity attributable to RiceBran Technologies shareholders:
|
||||||||
Preferred stock, 20,000,000 shares authorized and none issued
|
-
|
-
|
||||||
Common stock, no par value, 25,000,000 shares authorized, 9,537,415 and 9,383,571 shares issued and outstanding
|
262,895
|
261,299
|
||||||
Accumulated deficit
|
(250,738
|
)
|
(242,470
|
)
|
||||
Accumulated other comprehensive loss
|
(4,889
|
)
|
(3,157
|
)
|
||||
Total equity attributable to RiceBran Technologies shareholders
|
7,268
|
15,672
|
||||||
Total liabilities, temporary equity and equity
|
$
|
33,635
|
$
|
45,913
|
2015
|
2014
|
|||||||
Revenues
|
$
|
39,896
|
$
|
40,108
|
||||
Cost of goods sold
|
31,826
|
35,639
|
||||||
Gross profit
|
8,070
|
4,469
|
||||||
Operating expenses:
|
||||||||
Selling, general and administrative
|
12,567
|
14,354
|
||||||
Depreciation and amortization
|
1,779
|
2,879
|
||||||
Total operating expenses
|
14,346
|
17,233
|
||||||
Loss from operations
|
(6,276
|
)
|
(12,764
|
)
|
||||
Other income (expense):
|
||||||||
Interest income
|
107
|
115
|
||||||
Interest expense - accreted on debt converted to equity
|
-
|
(6,323
|
)
|
|||||
Interest expense - other
|
(3,101
|
)
|
(4,011
|
)
|
||||
Change in fair value of derivative warrant and conversion liabilities
|
1,001
|
(1,209
|
)
|
|||||
Loss on extinguishment
|
(1,904
|
)
|
(906
|
)
|
||||
Financing expense
|
-
|
(2,072
|
)
|
|||||
Foreign currency exchange, net
|
(370
|
)
|
(174
|
)
|
||||
Other income
|
167
|
12
|
||||||
Other expense
|
(376
|
)
|
(599
|
)
|
||||
Total other income (expense)
|
(4,476
|
)
|
(15,167
|
)
|
||||
Loss before income taxes
|
(10,752
|
)
|
(27,931
|
)
|
||||
Income tax benefit
|
176
|
1,304
|
||||||
Net loss
|
(10,576
|
)
|
(26,627
|
)
|
||||
Net loss attributable to noncontrolling interest in Nutra SA
|
2,308
|
3,598
|
||||||
Net loss attributable to RiceBran Technologies shareholders
|
$
|
(8,268
|
)
|
$
|
(23,029
|
)
|
||
Loss per share attributable to RiceBran Technologies shareholders
|
||||||||
Basic
|
$
|
(0.90
|
)
|
$
|
(3.96
|
)
|
||
Diluted
|
$
|
(0.90
|
)
|
$
|
(3.96
|
)
|
||
Weighted average number of shares outstanding
|
||||||||
Basic
|
9,187,983
|
5,809,364
|
||||||
Diluted
|
9,187,983
|
5,809,364
|
2015
|
2014
|
|||||||
Net loss
|
$
|
(10,576
|
)
|
$
|
(26,627
|
)
|
||
Other comprehensive loss - foreign currency translation, net of tax
|
(2,573
|
)
|
(1,404
|
)
|
||||
Comprehensive loss, net of tax
|
(13,149
|
)
|
(28,031
|
)
|
||||
Comprehensive loss attributable to noncontrolling interest, net of tax
|
3,147
|
4,081
|
||||||
Total comprehensive loss attributable to RiceBran Technologies shareholders
|
$
|
(10,002
|
)
|
$
|
(23,950
|
)
|
Common Stock
|
Accumulated
|
Accumulated
Other Comp-
|
Total
|
|||||||||||||||||
Shares
|
Amount
|
Deficit
|
rehensive Loss
|
Equity
|
||||||||||||||||
Balance, January 1, 2014
|
2,832,014
|
$
|
227,513
|
$
|
(219,441
|
)
|
$
|
(2,236
|
)
|
$
|
5,836
|
|||||||||
Share-based compensation, employees and directors
|
281,620
|
729
|
-
|
-
|
729
|
|||||||||||||||
Stock and warrant offering proceeds, net
|
2,786,781
|
13,296
|
-
|
-
|
13,296
|
|||||||||||||||
Warrant issued in private placement offering
|
-
|
430
|
-
|
-
|
430
|
|||||||||||||||
Issuance of shares to former warrant holders and a note holder
|
1,688,985
|
-
|
-
|
-
|
-
|
|||||||||||||||
Debt conversions
|
1,724,461
|
10,109
|
-
|
-
|
10,109
|
|||||||||||||||
Change in classification of warrants to equity from liability
|
-
|
8,902
|
-
|
-
|
8,902
|
|||||||||||||||
Other
|
69,710
|
320
|
-
|
-
|
320
|
|||||||||||||||
Foreign currency translation
|
-
|
-
|
-
|
(921
|
)
|
(921
|
)
|
|||||||||||||
Net loss
|
-
|
-
|
(23,029
|
)
|
-
|
(23,029
|
)
|
|||||||||||||
Balance, December 31, 2014
|
9,383,571
|
261,299
|
(242,470
|
)
|
(3,157
|
)
|
15,672
|
|||||||||||||
Share-based compensation, employees and directors
|
139,047
|
857
|
-
|
-
|
857
|
|||||||||||||||
Warrant issued to subordinated debt holders
|
-
|
699
|
-
|
-
|
699
|
|||||||||||||||
Other
|
14,797
|
40
|
-
|
-
|
40
|
|||||||||||||||
Foreign currency translation
|
-
|
-
|
-
|
(1,732
|
)
|
(1,732
|
)
|
|||||||||||||
Net loss
|
-
|
-
|
(8,268
|
)
|
-
|
(8,268
|
)
|
|||||||||||||
Balance, December 31, 2015
|
9,537,415
|
$
|
262,895
|
$
|
(250,738
|
)
|
$
|
(4,889
|
)
|
$
|
7,268
|
2015
|
2014
|
|||||||
Cash flow from operating activities:
|
||||||||
Net loss
|
$
|
(10,576
|
)
|
$
|
(26,627
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation
|
2,548
|
3,956
|
||||||
Amortization
|
1,515
|
2,593
|
||||||
Provision for doubtful accounts receivable
|
185
|
251
|
||||||
Share-based compensation, employees and directors
|
898
|
729
|
||||||
Interest accreted
|
455
|
7,058
|
||||||
Change in fair value of derivative warrant and conversion liabilities
|
(1,001
|
)
|
1,209
|
|||||
Loss on extinguishment
|
1,904
|
906
|
||||||
Financing expense
|
-
|
2,072
|
||||||
Deferred tax benefit
|
(192
|
)
|
(1,304
|
)
|
||||
Other
|
75
|
169
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
63
|
(766
|
)
|
|||||
Inventories
|
(677
|
)
|
(138
|
)
|
||||
Accounts payable and accrued expenses
|
1,392
|
(215
|
)
|
|||||
Other
|
(383
|
)
|
40
|
|||||
Net cash used in operating activities
|
(3,794
|
)
|
(10,067
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Acquisition of HN, net of cash acquired
|
-
|
(725
|
)
|
|||||
Purchases of property
|
(1,068
|
)
|
(5,423
|
)
|
||||
Proceeds from sales of property
|
-
|
23
|
||||||
Net cash used in investing activities
|
(1,068
|
)
|
(6,125
|
)
|
||||
Cash flows from financing activities:
|
||||||||
Payments of debt
|
(23,823
|
)
|
(18,971
|
)
|
||||
Proceeds from issuance of debt
|
25,991
|
15,699
|
||||||
Proceeds from issuance of convertible debt and related warrants, net of costs
|
-
|
5,379
|
||||||
Proceeds from issuance of common stock and warrants, net of costs
|
-
|
13,296
|
||||||
Other
|
-
|
(329
|
)
|
|||||
Net cash provided by financing activities
|
2,168
|
15,074
|
||||||
Effect of exchange rate changes on cash and cash equivalents
|
154
|
(363
|
)
|
|||||
Net change in cash and cash equivalents
|
(2,540
|
)
|
(1,481
|
)
|
||||
Cash and cash equivalents, beginning of year
|
3,610
|
5,091
|
||||||
Cash and cash equivalents, end of year
|
$
|
1,070
|
$
|
3,610
|
||||
Supplemental disclosures:
|
||||||||
Cash paid for interest
|
$
|
1,817
|
$
|
2,628
|
||||
Cash paid for income taxes
|
26
|
-
|
2015
|
2014
|
|||||||
NUMERATOR (in thousands):
|
||||||||
Basic and diluted - net loss attributable to RiceBran Technologies shareholders
|
$
|
(8,268
|
)
|
$
|
(23,029
|
)
|
||
DENOMINATOR:
|
||||||||
Basic EPS - weighted average number of shares outstanding
|
9,187,983
|
5,809,364
|
||||||
Effect of dilutive securities outstanding
|
-
|
-
|
||||||
Diluted EPS - weighted average number of shares outstanding
|
9,187,983
|
5,809,364
|
||||||
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive-Stock options (average exercise price of $10.04 and $18.56 )
|
305,690
|
201,584
|
||||||
Warrants (average exercise price of $5.74 and $5.92)
|
6,879,792
|
4,651,380
|
||||||
Nonvested shares of common stock
|
282,929
|
87,167
|
||||||
7,468,411
|
4,940,131
|
Cash
|
$
|
1,800
|
||
Cash holdback for contingencies
|
200
|
|||
Convertible notes payable
|
2,785
|
|||
Total fair value of consideration transferred
|
4,785
|
|||
Financial assets, including acquired cash of $1,075
|
1,314
|
|||
Inventories
|
1,109
|
|||
Property
|
963
|
|||
Identified intangible asset estimate
|
3,847
|
|||
Deferred income taxes, net
|
(1,529
|
)
|
||
Financial liabilities
|
(1,709
|
)
|
||
Net recognized amounts of identifiable assets acquired
|
3,995
|
|||
Goodwill - USA segment
|
$
|
790
|
December 31,
|
||||||||
2015
|
2014
|
|||||||
Cash and cash equivalents
|
$
|
104
|
$
|
269
|
||||
Other current assets (restricted $1,003 and $1,980)
|
2,760
|
4,735
|
||||||
Property, net (restricted $2,102 and $3,727)
|
9,502
|
15,258
|
||||||
Goodwill and intangibles, net
|
2,468
|
3,722
|
||||||
Other noncurrent assets
|
43
|
34
|
||||||
Total assets
|
$
|
14,877
|
$
|
24,018
|
||||
Current liabilities
|
$
|
4,647
|
$
|
5,346
|
||||
Current portion of long-term debt (nonrecourse)
|
2,750
|
4,758
|
||||||
Long-term debt, less current portion (nonrecourse)
|
3,553
|
6,203
|
||||||
Total liabilities
|
$
|
10,950
|
$
|
16,307
|
2015
|
2014
|
|||||||
Redeemable noncontrolling interest in Nutra SA, beginning of period
|
$
|
2,643
|
$
|
7,177
|
||||
Investors' interest in net loss of Nutra SA
|
(2,308
|
)
|
(3,598
|
)
|
||||
Investors' interest in accumulated other comprehensive loss of Nutra SA
|
(839
|
)
|
(483
|
)
|
||||
Investors' purchase of additional units
|
-
|
120
|
||||||
Accumulated Yield classified as other current liability
|
573
|
(573
|
)
|
|||||
Redeemable noncontrolling interest in Nutra SA, end of period
|
$
|
69
|
$
|
2,643
|
||||
Investors' average interest in Nutra SA during the period
|
32.9
|
%
|
40.0
|
%
|
||||
Investors' interest in Nutra SA as of period end
|
32.0
|
%
|
34.7
|
%
|
As of December 31,
|
||||||||
2015
|
2014
|
|||||||
Finished goods
|
$
|
1,575
|
$
|
1,103
|
||||
Work in process
|
270
|
380
|
||||||
Raw materials
|
1,259
|
1,441
|
||||||
Packaging supplies
|
753
|
584
|
||||||
Total inventories
|
$
|
3,857
|
$
|
3,508
|
As of December 31,
|
|||||||||
2015
|
2014
|
Estimated Useful Lives
|
|||||||
Land
|
$
|
323
|
$
|
364
|
|||||
Furniture and fixtures
|
433
|
539
|
5-10 years
|
||||||
Plant
|
13,122
|
15,942
|
25-30 years, or life of lease
|
||||||
Computer and software
|
1,594
|
1,701
|
3-5 years
|
||||||
Leasehold improvements
|
640
|
568
|
4-7 years or life of lease
|
||||||
Machinery and equipment
|
17,782
|
21,880
|
5-10 years
|
||||||
Subtotal
|
33,894
|
40,994
|
|||||||
Less accumulated depreciation
|
15,566
|
16,241
|
|||||||
Property, net
|
$
|
18,328
|
$
|
24,753
|
USA Segment
|
Brazil Segment
|
Total | ||||||||||||||||||||||
Patents
|
Trademarks
|
Customer
Lists
|
Trademarks
|
Customer
Lists
|
Intangible
Assets
|
|||||||||||||||||||
December 31, 2015
|
||||||||||||||||||||||||
Cost
|
$
|
1,498
|
$
|
76
|
$
|
6,524
|
$
|
2,607
|
$
|
953
|
$
|
11,658
|
||||||||||||
Accumulated amortization
|
(1,215
|
)
|
-
|
(5,658
|
)
|
(2,607
|
)
|
(953
|
)
|
(10,433
|
)
|
|||||||||||||
Net book value
|
$
|
283
|
$
|
76
|
$
|
866
|
$
|
-
|
$
|
-
|
$
|
1,225
|
||||||||||||
December 31, 2014
|
||||||||||||||||||||||||
Cost
|
$
|
1,697
|
$
|
76
|
$
|
6,524
|
$
|
2,607
|
$
|
953
|
$
|
11,857
|
||||||||||||
Accumulated amortization
|
(1,296
|
)
|
-
|
(4,343
|
)
|
(2,547
|
)
|
(931
|
)
|
(9,117
|
)
|
|||||||||||||
Net book value
|
$
|
401
|
$
|
76
|
$
|
2,181
|
$
|
60
|
$
|
22
|
$
|
2,740
|
||||||||||||
Estimated useful lives
|
17 years
|
Indefinite
|
3 - 7 years
|
7 years
|
7 years
|
2015
|
2014
|
|||||||
Goodwill, beginning of period
|
$
|
4,431
|
$
|
4,139
|
||||
USA segment - Acquisition of HN
|
-
|
790
|
||||||
Brazil segment - Effect of foreign currency translation
|
(1,173
|
)
|
(498
|
)
|
||||
Goodwill, end of period
|
$
|
3,258
|
$
|
4,431
|
2015
|
2014
|
|||||||
Corporate segment:
|
||||||||
Senior revolving loan
|
$
|
1,617
|
$
|
-
|
||||
Senior term note, net
|
1,407
|
-
|
||||||
Subordinated notes, net, maturing in May 2018, principal $6.2 million
|
6,310
|
-
|
||||||
Subordinated notes, net, due in July 2016, principal $0.2 million
|
205
|
4,978
|
||||||
Other
|
116
|
157
|
||||||
9,655
|
5,135
|
|||||||
Brazil segment:
|
||||||||
Capital expansion loans
|
2,067
|
3,629
|
||||||
Working capital lines of credit
|
828
|
2,408
|
||||||
Advances on customer export orders
|
1,310
|
1,810
|
||||||
Special tax programs
|
2,064
|
3,016
|
||||||
Other
|
34
|
98
|
||||||
6,303
|
10,961
|
|||||||
Total debt
|
15,958
|
16,096
|
||||||
Current portion
|
5,050
|
4,808
|
||||||
Long-term portion
|
$
|
10,908
|
$
|
11,288
|
Corporate
Segment
|
Brazil
Segment
|
Total
|
||||||||||
2016
|
$
|
2,339
|
$
|
2,751
|
$
|
5,090
|
||||||
2017
|
1,821
|
637
|
2,458
|
|||||||||
2018
|
6,607
|
555
|
7,162
|
|||||||||
2019
|
-
|
493
|
493
|
|||||||||
2020
|
-
|
416
|
416
|
|||||||||
Thereafter
|
-
|
1,451
|
1,451
|
|||||||||
10,767
|
6,303
|
17,070
|
||||||||||
Debt issuance costs
|
(1,112
|
)
|
-
|
(1,112
|
)
|
|||||||
Total debt
|
$
|
9,655
|
$
|
6,303
|
$
|
15,958
|
Options
|
Equity and Liability Warrants
|
|||||||||||||||||||||||
Shares
Under
Options
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Shares
Under
Warrants
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
|||||||||||||||||||
Outstanding, January 1, 2014
|
179,437
|
$
|
24.28
|
6.2
|
2,406,282
|
$
|
6.33
|
4.5
|
||||||||||||||||
Granted or issued
|
141,134
|
4.77
|
4,262,436
|
5.44
|
||||||||||||||||||||
Exercised
|
-
|
NA
|
-
|
NA
|
||||||||||||||||||||
Forfeited, expired or cancelled
|
(50,929
|
)
|
34.61
|
(164,759
|
)
|
5.24
|
||||||||||||||||||
Outstanding, December 31, 2014
|
269,642
|
12.12
|
7.9
|
6,503,959
|
5.77
|
4.3
|
||||||||||||||||||
Granted or issued
|
110,993
|
3.26
|
589,669
|
5.25
|
||||||||||||||||||||
Exercised
|
-
|
NA
|
-
|
NA
|
||||||||||||||||||||
Forfeited, expired or cancelled
|
(22,838
|
)
|
20.21
|
-
|
NA
|
|||||||||||||||||||
Outstanding, December 31, 2015
|
357,797
|
$
|
8.86
|
7.8
|
7,093,628
|
$
|
5.73
|
3.4
|
||||||||||||||||
Exercisable, December 31, 2015
|
188,301
|
$
|
13.14
|
6.6
|
7,093,628
|
$
|
5.73
|
3.4
|
2015
|
2014
|
|||||||
Stock Options:
|
||||||||
Employees
|
$
|
128
|
$
|
132
|
||||
Executive officers
|
117
|
136
|
||||||
Consultants
|
1
|
4
|
||||||
Directors
|
-
|
11
|
||||||
Stock:
|
||||||||
Directors
|
269
|
332
|
||||||
Executive officers
|
342
|
114
|
||||||
Total share-based compensation expense
|
$
|
857
|
$
|
729
|
2015
|
2014
|
|||||||
Assumed volatility
|
90.7% - 112.5%
|
119.9%
|
|
|||||
(112.0% weighted average)
|
||||||||
Assumed risk free interest rate
|
0.9% - 1.6%
|
|
1.7%
|
|
||||
(1.6% weighted average)
|
||||||||
Average expected life of options (in years)
|
6.2
|
6.2
|
||||||
Expected dividends
|
-
|
-
|
||||||
Forfeiture rate
|
5%
|
|
5%
|
|
As of December 31, 2015
|
||||||||||||||||||||||||||
Outstanding
|
Exercisable
|
|||||||||||||||||||||||||
Range of Exercise
Prices
|
Shares
Underlying
Options
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Shares
Underlying
Options
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
||||||||||||||||||||
$
|
1.98 to $2.97
|
34,862
|
$
|
2.83
|
9.7
|
3,849
|
2.85
|
9.7
|
||||||||||||||||||
$
|
2.98 to $3.47
|
75,243
|
3.47
|
9.5
|
12,540
|
3.47
|
9.5
|
|||||||||||||||||||
$
|
3.48 to $4.77
|
131,134
|
4.77
|
8.6
|
58,236
|
4.77
|
8.6
|
|||||||||||||||||||
$
|
4.78 to $16.00
|
109,267
|
15.77
|
5.3
|
105,449
|
15.84
|
5.2
|
|||||||||||||||||||
$
|
28.00
|
1,457
|
28.00
|
7.2
|
1,457
|
28.00
|
7.2
|
|||||||||||||||||||
$
|
40.00
|
2,834
|
40.00
|
5.8
|
2,834
|
40.00
|
5.8
|
|||||||||||||||||||
$
|
74.00
|
2,500
|
74.00
|
5.2
|
2,436
|
74.00
|
5.2
|
|||||||||||||||||||
$
|
242.00
|
500
|
242.00
|
0.0
|
500
|
242.00
|
0.0
|
|||||||||||||||||||
$
|
4.77 to $242.00
|
357,797
|
$
|
8.86
|
7.8
|
187,301
|
$
|
13.14
|
6.6
|
Equity Warrants
|
Liability Warrants
|
|||||||||||||||||||||||
Shares
Underlying
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Shares
Underlying
|
Weighted
Average
Exercise Price
|
Weighted
Average
Remaining
Contractual
Life
(Years)
|
|||||||||||||||||||
Balance, January 1, 2014
|
1,815,034
|
$
|
6.69
|
5.0
|
591,248
|
$
|
5.24
|
2.9
|
||||||||||||||||
Granted
|
4,262,436
|
5.44
|
-
|
NA
|
||||||||||||||||||||
Exercised
|
-
|
NA
|
-
|
NA
|
||||||||||||||||||||
Forfeited, expired or cancelled
|
-
|
NA
|
(164,759
|
)
|
5.24
|
|||||||||||||||||||
Outstanding, December 31, 2014
|
6,077,470
|
5.81
|
4.4
|
426,489
|
5.24
|
2.9
|
||||||||||||||||||
Granted
|
289,669
|
5.25
|
300,000
|
5.25
|
||||||||||||||||||||
Exercised
|
-
|
NA
|
-
|
NA
|
||||||||||||||||||||
Forfeited, expired or cancelled
|
-
|
NA
|
-
|
NA
|
||||||||||||||||||||
Outstanding, December 31, 2015
|
6,367,139
|
$
|
5.73
|
3.4
|
726,489
|
$
|
5.24
|
2.9
|
||||||||||||||||
Exercisable, December 31, 2015
|
6,367,139
|
$
|
5.73
|
3.4
|
726,489
|
$
|
5.24
|
2.9
|
· | In June 2014, we issued warrants to purchase 265,000 shares of common stock (exercise price of $5.25 per share and June 2019 expiration). |
· | In May 2015, we issued a warrant to purchase 300,000 shares of common stock (exercise price of $5.25, May 2020 expiration) to our senior lender. |
· | In May 2015, we issued warrants to purchase 289,669 shares of common stock (exercise price of $5.25, May 2020 expiration) in conjunction with the extinguishment and reissuance of certain subordinated notes. |
Outstanding
|
Exercisable
|
||||||||||||||||||||||||||
Range of
Exercise Prices
|
Type of
Warrant
|
Shares
Under
Warrants
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Shares
Under
Warrants
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
||||||||||||||||||||
$
|
5.24
|
Liability (1)
|
426,489
|
$
|
5.24
|
1.9
|
426,489
|
$
|
5.24
|
1.9
|
|||||||||||||||||
$
|
5.25
|
Liability (2)
|
300,000
|
5.25
|
4.4
|
300,000
|
5.25
|
4.4
|
|||||||||||||||||||
$
|
5.25 to $5.87
|
Equity
|
4,296,339
|
5.36
|
3.7
|
4,296,339
|
5.36
|
3.7
|
|||||||||||||||||||
$
|
6.55 to $6.63
|
Equity
|
2,055,767
|
6.55
|
3.0
|
2,055,767
|
6.55
|
3.0
|
|||||||||||||||||||
$
|
16.00 to $16.80
|
Equity
|
12,004
|
16.40
|
2.5
|
12,004
|
16.40
|
2.5
|
|||||||||||||||||||
$
|
46.80
|
Equity
|
3,029
|
46.80
|
1.0
|
3,029
|
46.80
|
1.0
|
|||||||||||||||||||
7,093,628
|
$
|
5.73
|
3.4
|
7,093,628
|
$
|
5.73
|
3.4
|
(1) | The warrants contain full ratchet anti-dilution provisions and are classified as derivative warrant liabilities in our balance sheets. Under the anti-dilution clauses contained in these warrants, in the event of equity issuances at prices below the exercise prices of these warrants, we may be required to lower the exercise price on these warrants and increase the number of shares underlying these warrants. Equity issuances may include issuances of our common stock, certain awards of options to employees, and issuances of warrants and/or other convertible instruments. As a result of February 2016 equity issuances, in February 2016, we were required to lower the exercise price on these warrants to $1.50 per share and increase the number of shares of common stock underlying these warrants to 1,489,867 shares. |
(2) | The warrant, issued in May 2015 to the Lender, contains a most favored nations anti-dilution provisions Under that provision, in the event of issuances of options and/or convertible instruments with anti-dilution provision (providing for the adjustment of the exercise price, conversion price or other price or rate at which shares of common stock thereunder may be purchased, acquired or converted, and/or any upward adjustment in the number of shares of common stock issuable) we may be required to lower the exercise price on this warrant and and/or increase the number of shares underlying this warrant. The warrant is classified as derivative warrant liabilities in our balance sheets. |
As of December 31,
|
||||||||
2015
|
2014
|
|||||||
United States
|
||||||||
Net operating loss carryforwards
|
$
|
4,007
|
$
|
2,503
|
||||
Gain on sale of membership interests in Nutra SA
|
366
|
369
|
||||||
Stock options and warrants
|
719
|
625
|
||||||
Property
|
(174
|
)
|
(80
|
)
|
||||
Intangible assets
|
(274
|
)
|
(797
|
)
|
||||
Capitalized expenses
|
462
|
525
|
||||||
Debt and deferred financing
|
329
|
(116
|
)
|
|||||
Other
|
345
|
642
|
||||||
Net deferred tax assets
|
5,780
|
3,671
|
||||||
Less: Valuation allowance
|
(5,814
|
)
|
(3,896
|
)
|
||||
Deferred tax asset (liability)
|
(34
|
)
|
(225
|
)
|
||||
Brazil
|
||||||||
Property
|
(731
|
)
|
(1,141
|
)
|
||||
Intangible assets
|
-
|
(28
|
)
|
|||||
Net operating loss carryforwards
|
4,320
|
4,666
|
||||||
Other
|
360
|
370
|
||||||
Net deferred tax assets
|
3,949
|
3,867
|
||||||
Less: Valuation allowance
|
(3,949
|
)
|
(3,867
|
)
|
||||
Deferred tax asset (liability)
|
$
|
-
|
$
|
-
|
2015
|
2014
|
|||||||
Foreign
|
$
|
(5,136
|
)
|
$
|
(10,504
|
)
|
||
Domestic
|
(5,616
|
)
|
(17,427
|
)
|
||||
Loss before income taxes
|
$
|
(10,752
|
)
|
$
|
(27,931
|
)
|
2015
|
2014
|
|||||||
Income tax benefit at federal statutory rate
|
$
|
(3,656
|
)
|
$
|
(9,496
|
)
|
||
Increase (decrease) resulting from:
|
||||||||
State tax benefit, net of federal tax effect
|
(176
|
)
|
(206
|
)
|
||||
Change in valuation allowance
|
3,601
|
(46,511
|
)
|
|||||
Expiration of U.S. net operating losses
|
101
|
41,756
|
||||||
Adjustment to fixed asset deferred balance
|
-
|
7,450
|
||||||
Adjustment to intangible deferred balances
|
-
|
484
|
||||||
Reduction in deferred balances for forfeited, expired or cancelled options
|
75
|
597
|
||||||
Nontaxable fair value adjustment
|
(340
|
)
|
411
|
|||||
Nondeductible debt issuance expenses
|
19
|
3,179
|
||||||
Impact of state rate changes
|
16
|
917
|
||||||
Nondeductible expenses
|
91
|
37
|
||||||
Adjustments to Brazil deferred balances
|
-
|
15
|
||||||
Adjustments to U.S. deferred balances
|
93
|
63
|
||||||
Income tax benefit
|
$
|
(176
|
)
|
$
|
(1,304
|
)
|
2015
|
||||||||||||||||||||
Corporate
|
USA
|
Brazil
|
Intersegment
|
Consolidated
|
||||||||||||||||
Revenues
|
$
|
-
|
$
|
23,341
|
$
|
16,601
|
$
|
(46
|
)
|
$
|
39,896
|
|||||||||
Cost of goods sold
|
-
|
15,923
|
15,949
|
(46
|
)
|
31,826
|
||||||||||||||
Gross profit
|
-
|
7,418
|
652
|
-
|
8,070
|
|||||||||||||||
Depreciation and amortization (in selling, generaland administrative)
|
(79
|
)
|
(1,569
|
)
|
(131
|
)
|
-
|
(1,779
|
)
|
|||||||||||
Other operating expenses
|
(4,892
|
)
|
(4,288
|
)
|
(3,387
|
)
|
-
|
(12,567
|
)
|
|||||||||||
Income (loss) from operations
|
$
|
(4,971
|
)
|
$
|
1,561
|
$
|
(2,866
|
)
|
$
|
-
|
$
|
(6,276
|
)
|
|||||||
Net income (loss) attributable to RiceBran Technologies shareholders
|
$
|
(6,948
|
)
|
$
|
1,561
|
$
|
(2,881
|
)
|
$
|
-
|
$
|
(8,268
|
)
|
|||||||
Interest expense
|
(1,404
|
)
|
-
|
(1,697
|
)
|
-
|
(3,101
|
)
|
||||||||||||
Depreciation (in cost of goods sold)
|
-
|
(890
|
)
|
(1,394
|
)
|
-
|
(2,284
|
)
|
||||||||||||
Purchases of property
|
94
|
474
|
500
|
-
|
1,068
|
|||||||||||||||
Property, net, end of period
|
418
|
8,408
|
9,502
|
-
|
18,328
|
|||||||||||||||
Goodwill, end of period
|
-
|
790
|
2,468
|
-
|
3,258
|
|||||||||||||||
Intangible assets, net, end of period
|
-
|
1,225
|
-
|
-
|
1,225
|
|||||||||||||||
Total assets, end of period
|
3,203
|
15,554
|
14,878
|
-
|
33,635
|
2014
|
||||||||||||||||||||
Corporate
|
USA
|
Brazil
|
Intersegment
|
Consolidated
|
||||||||||||||||
Revenues
|
$
|
-
|
$
|
23,096
|
$
|
17,012
|
$
|
-
|
$
|
40,108
|
||||||||||
Cost of goods sold
|
-
|
16,124
|
19,515
|
-
|
35,639
|
|||||||||||||||
Gross profit
|
-
|
6,972
|
(2,503
|
)
|
-
|
4,469
|
||||||||||||||
Depreciation and amortization (in selling, generaland administrative)
|
(52
|
)
|
(2,137
|
)
|
(690
|
)
|
-
|
(2,879
|
)
|
|||||||||||
Other operating expenses
|
(5,941
|
)
|
(4,133
|
)
|
(4,280
|
)
|
-
|
(14,354
|
)
|
|||||||||||
Income (loss) from operations
|
$
|
(5,993
|
)
|
$
|
702
|
$
|
(7,473
|
)
|
$
|
-
|
$
|
(12,764
|
)
|
|||||||
Net income (loss) attributable to RiceBran Technologies shareholders
|
$
|
(16,825
|
)
|
$
|
702
|
$
|
(6,906
|
)
|
$
|
-
|
$
|
(23,029
|
)
|
|||||||
Interest expense
|
(7,949
|
)
|
-
|
(2,385
|
)
|
-
|
(10,334
|
)
|
||||||||||||
Depreciation (in cost of goods sold)
|
-
|
(1,022
|
)
|
(2,648
|
)
|
-
|
(3,670
|
)
|
||||||||||||
Purchases of property
|
152
|
2,251
|
3,020
|
-
|
5,423
|
|||||||||||||||
Property, net, end of period
|
135
|
9,360
|
15,258
|
-
|
24,753
|
|||||||||||||||
Goodwill, end of period
|
-
|
790
|
3,641
|
-
|
4,431
|
|||||||||||||||
Intangible assets, net, end of period
|
-
|
2,658
|
82
|
-
|
2,740
|
|||||||||||||||
Total assets, end of period
|
4,041
|
17,854
|
24,018
|
-
|
45,913
|
2015
|
2014
|
|||||||
United States
|
$
|
21,978
|
$
|
21,381
|
||||
Brazil
|
9,548
|
14,257
|
||||||
Other international
|
8,370
|
4,470
|
||||||
Total revenues
|
$
|
39,896
|
$
|
40,108
|
● | Level 1 – inputs include quoted prices for identical instruments and are the most observable. |
● | Level 2 – inputs include quoted prices for similar assets and observable inputs such as interest rates, currency exchange rates and yield curves. |
● | Level 3 – inputs are not observable in the market and include management’s judgments about the assumptions market participants would use in pricing the asset or liability. |
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Total liabilities at fair value, as of December 31, 2015 - derivative warrant liabilities
|
$
|
-
|
$
|
-
|
$
|
(678
|
)
|
$
|
(678
|
)
|
||||||
Total liabilities at fair value, as of December 31, 2014 - derivative warrant liabilities
|
$
|
-
|
$
|
-
|
$
|
(955
|
)
|
$
|
(955
|
)
|
December 31, 2015
|
December 31, 2014
|
|||||||
Risk-free interest rate
|
0.9% - 1.2%
|
|
0.1% - 1.0%
|
|
||||
(1.1% weighted average)
|
(0.7% weighted average)
|
|||||||
Expected volatility
|
71% - 89%
|
|
95%
|
|
||||
(78% weighted average)
|
Fair Value
as of
Beginning
of Period
|
Total
Realized and
Unrealized
Gains (Losses) |
Issuance of
New
Instruments
|
Net
Transfers (Into) Out of Level 3 |
Fair Value,
at End of
Period
|
Change in
Unrealized
Gains
(Losses) on
Instruments
Still Held
|
|||||||||||||||||||
2015
|
(1
|
)
|
||||||||||||||||||||||
Derivative warrant liability
|
$
|
(955
|
)
|
$
|
1,001
|
$
|
(724
|
)
|
$
|
-
|
$
|
(678
|
)
|
$
|
-
|
|||||||||
Derivative conversion liability
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||
Total Level 3 fair value
|
$
|
(955
|
)
|
$
|
1,001
|
$
|
(724
|
)
|
$
|
-
|
$
|
(678
|
)
|
$
|
-
|
|||||||||
2014
|
(1
|
)
|
||||||||||||||||||||||
Derivative warrant liability
|
$
|
(1,685
|
)
|
$
|
(1,151
|
)
|
$
|
(7,021
|
)
|
$
|
8,902
|
(2)
|
$
|
(955
|
)
|
$
|
546
|
|||||||
Derivative conversion liability
|
-
|
(58
|
)
|
(589
|
)
|
647
|
(3)
|
-
|
NA
|
|||||||||||||||
Total Level 3 fair value
|
$
|
(1,685
|
)
|
$
|
(1,209
|
)
|
$
|
(7,610
|
)
|
$
|
9,549
|
$
|
(955
|
)
|
$
|
546
|
(1) | Included in change in fair value of derivative warrant and conversion liabilities in our consolidated statements of operations. |
(2) | Represents transfers to equity as a result of increases in authorized and unissued shares of common stock available for settlement of certain warrants. |
(3) | Represents reduction in conversion liability as a result of debt conversions. |
(i)
|
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
|
(ii)
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
|
(iii) | provide reasonable assurance regarding prevention, or timely detection, of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. |
Exhibit
Number
|
Exhibit Description
|
|
1.01
|
Warrant Agreement dated December 18, 2013, with American Stock Transfer & Trust Company. (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed December 18, 2013)
|
|
2.01
|
Quotas Purchase and Sale Agreement, dated January 31, 2008, with Quota Holders of Irgovel - Industria Riograndens De Oleos Vegetais Ltda (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed on August 11, 2008 and on registrant’s annual report on Form 10-K, filed on March 17, 2008)
|
|
3.01.1
|
Restated and Amended Articles of Incorporation as filed with the Secretary of State of California on December 13, 2001 (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-KSB, filed on April 16, 2002)
|
|
3.01.2
|
Certificate of Amendment of Articles of Incorporation as filed with the Secretary of State of California on August 4, 2003 (incorporated herein by reference to exhibits previously filed on registrant’s Registration Statement on Form SB-2, filed on November 18, 2005)
|
|
3.01.3
|
Certificate of Amendment of Articles of Incorporation as filed with the Secretary of State of California on October 31, 2003 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-QSB, filed on November 19, 2003)
|
|
3.01.4
|
Certificate of Amendment of Articles of Incorporation as filed with the Secretary of State of California on September 29, 2005 (incorporated herein by reference to exhibits previously filed on registrant’s Registration Statement on Form SB-2, filed on November 18, 2005)
|
|
3.01.5
|
Certificate of Amendment of Articles of Incorporation as filed with the Secretary of State of California on August 20, 2007 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed on August 14, 2007)
|
|
3.01.6
|
Certificate of Amendment of Articles of Incorporation as filed with the Secretary of State of California on June 30, 2011 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on July 5, 2011)
|
|
3.01.7
|
Certificate of Amendment of Articles of Incorporation filed with the Secretary of State of California on July 12, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed August 14, 2013)
|
|
3.01.8
|
Certificate of Amendment of Articles of Incorporation filed with the Secretary of State of California on May 30, 2014 (incorporated herein by reference to exhibits previously filed on registrant’s registration statement on Form S-3 filed June 5, 2014)
|
|
3.02
|
Certificate of Designation of the Rights, Preferences, and Privileges of the Series A Preferred Stock as filed with the Secretary of State of California on December 13, 2001 (incorporated herein by reference to exhibits previously filed on registrant’s Registration Statement on Form SB-2, filed on June 4, 2002)
|
|
3.03
|
Certificate of Determination, Preferences and Rights of Series B Convertible Preferred Stock as filed with the Secretary of State of California on October 4, 2005 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on October 4, 2005)
|
|
3.04
|
Certificate of Determination, Preferences and Rights of Series C Convertible Preferred Stock as filed with the Secretary of State of California on May 10, 2006 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2006)
|
|
3.05
|
Certificate of Determination, Preferences and Rights of the Series D Convertible Preferred Stock, as filed with the Secretary of State of California on October 17, 2008 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on October 20, 2008)
|
|
3.06
|
Certificate of Determination, Preferences and Rights of the Series E Convertible Preferred Stock, as filed with the Secretary of State of California on May 7, 2009 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 8, 2009)
|
|
3.07
|
Certificate of Determination, Preferences and Rights of the Series F Convertible Preferred Stock, as filed with the Secretary of State of California on February 18, 2016 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on February 23, 2016)
|
|
3.08.1
|
Bylaws (incorporated herein by reference to exhibits previously filed on registrant’s Registration Statement on Form SB-2, filed on June 12, 2006)
|
|
3.08.2
|
Amendment of Bylaws effective June 19, 2007 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on June 25, 2007)
|
3.08.3
|
Amendment of Bylaws effective December 4, 2009 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on December 10, 2009)
|
|
3.09
|
Certificate of Ownership dated October 3, 2012 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on October 10, 2012)
|
|
4.01
|
Common Stock Warrant issued to Hillair Capital Investments L.P. (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on January 23, 2012)
|
|
4.02
|
Form of warrant to purchase shares issued to holders of secured convertible promissory notes (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on January 23, 2012)
|
|
4.03
|
Common Stock Warrant issued to Hillair Capital Investments L.P. (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on August 6, 2012)
|
|
4.04
|
Warrant Agreement by and between RiceBran Technologies and American Stock Transfer & Trust Company and Form of Warrant Certificate (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on December 18, 2013)
|
|
4.05
|
Form of Convertible Promissory Note dated March 20, 2014 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on March 21, 2014)
|
|
4.06
|
Form of Warrant (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on March 21, 2014)
|
|
4.07
|
Form of Warrant (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on June 20, 2014)
|
|
4.08
|
Form of Warrant (incorporated herein by reference to exhibits previously filed on registrant’s current report on 8-K, filed on September 30, 2014)
|
|
4.09
|
Form of Warrant (incorporated herein by reference to exhibits previously filed on registrant’s current report on 8-K, filed on February 17, 2016)
|
|
10.01
|
*
|
Employment Agreement with W. John Short (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on July 10, 2009)
|
10.02
|
*
|
First Amendment of Employment Agreement with W. John Short (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on July 10, 2009)
|
10.03
|
*
|
Second Amendment of Employment Agreement with W. John Short (incorporated herein by reference to previously filed Form 10-Q, filed on May 11, 2011)
|
10.04
|
*
|
Third Amendment to Employment Agreement with W. John Short dated July 2, 2010 (incorporated herein by reference to exhibit 10.1 previously filed on registrant’s current report on Form 8-K, filed on July 8, 2010)
|
10.05
|
*
|
Fourth Amendment to Employment Agreement with W. John Short dated July 15, 2011 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on July 20, 2011)
|
10.06
|
*
|
Employment Agreement with Jerry Dale Belt dated June 8, 2010 (incorporated herein by reference to exhibit 10.1 previously filed on registrant’s current report on Form 8-K, filed on June 8, 2010)
|
10.07
|
*
|
First Amendment to Employment Agreement with Jerry Dale Belt dated July 15, 2011 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on July 20, 2011)
|
10.08
|
*
|
Second Amendment to Employment Agreement with Jerry Dale Belt dated February 14, 2012 (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 30, 2012)
|
10.09
|
*
|
Third Amendment to Employment Agreement with Jerry Dale Belt dated May 30, 2014 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on June 3, 2014)
|
10.10
|
*
|
Fourth Amendment to Employment Agreement with Jerry Dale Belt dated as of May 30, 2015 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on June 5, 2015)
|
10.11
|
Employment Agreement with Mark S. McKnight dated September 20, 2013 (incorporated herein by reference to exhibits previously filed on Amendment No. 1 to registrant’s annual report on Form 10-K, filed on April 30, 2014)
|
|
10.12
|
Amendment to Employment Agreement and Non-Competition Agreement for Mark S. McKnight dated December 30, 2013 (incorporated herein by reference to exhibits previously filed on Amendment No. 1 to registrant’s annual report on Form 10-K, filed on April 30, 2014)
|
|
10.13
|
*
|
2005 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on Form SB-2, filed on November 18, 2005)
|
10.14
|
*
|
Form of Non-Employee Director Stock Option Agreement under the 2005 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 17, 2008)
|
10.15
|
*
|
Form of Stock Option Agreement for 2005 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed on May 12, 2008)
|
10.16
|
*
|
Form of Restricted Stock Grant Agreement for 2005 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed on August 11, 2008)
|
10.17
|
2010 Equity Incentive Plan (incorporated herein by reference to previously filed Form 10-Q, filed on May 11, 2011)
|
|
10.18
|
Second Amendment of Investment Agreements for Nutra SA, LLC dated December 9, 2014 (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 31, 2015)
|
|
10.19
|
Second Amendment of Investment Agreements for Nutra SA, LLC dated as of August 11, 2015 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on August 13, 2015)
|
|
10.20
|
*
|
Form of Non-Employee Director Stock Option Agreement under the 2010 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 30, 2012)
|
10.21
|
Form of Stock Option Agreement for the 2010 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 30, 2012)
|
|
10.22
|
*
|
Form of Restricted Stock Grant Agreement for the 2010 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 30, 2012)
|
10.23
|
*
|
RiceBran Technologies 2014 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on August 25, 2014)
|
10.24
|
*
|
Form of Stock Option Agreement for 2014 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 31, 2015)
|
10.25
|
*
|
Form of Restricted Stock Award Agreement for 2014 Equity Incentive Plan (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 31, 2015)
|
10.26
|
*
|
Form of Indemnification Agreement for officers and directors (incorporated by reference to previously filed Form 10-Q, filed on May 11, 2011)
|
10.27
|
+
|
Nutra SA, LLC Membership Interest Purchase Agreement dated December 29, 2010 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K/A, filed on August 10, 2011)
|
10.28
|
Membership Interest Purchase Agreement dated April 2, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on April 5, 2013)
|
|
10.29
|
Form of Investor Rights Agreement (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on January 5, 2011)
|
|
10.30
|
License Agreement dated March 14, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on March 20, 2013)
|
|
10.31
|
Second Amended and Restated Limited Liability Agreement for Nutra SA, LL,C dated December 24, 2012 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on December 31, 2012)
|
|
10.32
|
Contribution and Subscription Agreement, dated December 24, 2012, regarding Nutra SA, LLC (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on December 31, 2012)
|
|
10.33
|
Amendment of Investment Agreements effective, dated October 31, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on November 8, 2013)
|
|
10.34
|
Second Amendment of Investment Agreements, dated as of August 11, 2015, (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on August 13, 2015)
|
|
10.35
|
Loan agreement between Industria Riograndens De Oleos Vegetais Ltd. and Banco do Brasil S.A. in the amount of R$2,784,838 with a Brazilian bank dated December 15, 2011, English translation from the original Portuguese (incorporated herein by reference to exhibits previously filed on registrant’s annual report on Form 10-K, filed on March 30, 2012)
|
|
10.36
|
Loan agreement between Industria Riograndens De Oleos Vegetais Ltd. and Banco do Brasil S.A. in the amount of R$6,676,012 dated December 15, 2011, English translation from the original Portuguese (incorporated herein by reference to exhibits previously filed on registrant’s Annual Report on Form 10-K, filed on March 30, 2012)
|
|
10.37
|
Sublicense Agreement with RBT PRO LLC and Wilmar (Shanghai) Biotechnology Research Development Center Co., Ltd. dated April 2, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on April 5, 2013)
|
|
10.38
|
Sublicense Agreement with RBT PRO LLC dated April 2, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on April 5, 2013)
|
10.39
|
Cross License Agreement with Wilmar (Shanghai) Biotechnology Research Development Center Co., Ltd. dated April 2, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on April 5, 2013)
|
|
10.40
|
Amended and Restated Limited Liability Company Agreement for RBT PRO LLC, dated April 2, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on April 5, 2013)
|
|
10.41
|
Senior Secured Revolving Credit Facility Agreement with TCA Global Credit Master Fund, LP, dated as of April 30, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 30, 2013)
|
|
10.42
|
Promissory Note issued to TCA Global Credit Master Fund, LP, dated as of April 30, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 30, 2013)
|
|
10.43
|
Form of Guaranty Agreement by Subsidiary Guarantors in favor of TCA Global Credit Master Fund, LP, dated as of April 30, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 30, 2013)
|
|
10.44
|
Security Agreement with TCA Global Credit Master Fund, LP, dated as of April 30, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 30, 2013)
|
|
10.45
|
Form of Security Agreement, dated as of April 30, 2013, by Subsidiary Guarantors and TCA Global Credit Master Fund, LP (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 30, 2013)
|
|
10.46
|
Form of Pledge with TCA Global Credit Master Fund, LP, dated as of April 30, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 30, 2013)
|
|
10.47
|
Amended and Restated Security Agreement, dated as of May 24, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed August 14, 2013)
|
|
10.48
|
Amended and Restated Note and Warrant Purchase Agreement, dated as of May 24, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed August 14, 2013)
|
|
10.49
|
Restated Subordination Agreement, dated as of May 24, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed August 14, 2013)
|
|
10.50
|
Subordination Agreement, dated as of May 12, 2015 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.51
|
Amendment to Loan Documents, dated as of May 12, 2015 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.52
|
Third Amended and Restated Security Agreement, dated as of May 12, 201, (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.53
|
Amendment 1 to Senior Secured Revolving Credit Facility Agreement with TCA Global Credit Master Fund, LP, dated July 18, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed August 14, 2013)
|
|
10.54
|
Promissory Note issued to TCA Global Credit Master Fund, LP, dated July 18, 2013(incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed August 14, 2013)
|
|
10.55
|
Acquisition and Stock Purchase Agreement with the Shareholders of H&N Distribution, Inc., dated September 24, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on September 26, 2013)
|
|
10.56
|
Promissory Note issued to TCA Global Credit Master Fund, LP dated October 11, 2013 (incorporated herein by reference to exhibits previously filed on registrant’s quarterly report on Form 10-Q, filed November 12, 2013)
|
|
10.57
|
Underwriting Agreement dated December 12, 2013, with Maxim Group, LLC, as representative of the several underwriters (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on December 18, 2013)
|
|
10.58
|
Note and Warrant Purchase Agreement dated March 20, 2014 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on March 21, 2014)
|
|
10.59
|
Registration Rights Agreement dated March 20, 2014 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on March 21, 2014)
|
|
10.60
|
Securities Purchase Agreement (incorporated herein by reference to exhibits previously filed on registrant’s current report on 8-K, filed on October 1, 2014)
|
|
10.61
|
Form of Registration Rights Agreement (incorporated herein by reference to exhibits previously filed on registrant’s current report on 8-K, filed on October 1, 2014)
|
10.62
|
Loan, Guarantor and Security Agreement with Full Circle Capital Corporation, dated as of May 12, 2015 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.63
|
Term Loan Note, dated as of May 12, 2015, issued to Full Circle Capital Corporation (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.64
|
Revolving Loan Note, dated as of May 12, 2015, issued to Full Circle Capital Corporation (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.65
|
Intellectual Property Security Agreement, dated as of May 12, 2015 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.66
|
Pledge Agreement dated as of May 12, 2015, with Full Circle Capital Corporation (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.67
|
Lender Warrant dated as of May 12, 2015 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on May 15, 2015)
|
|
10.68
|
Exclusive Supply and Cooperation Agreement ,dated February 8, 2016, with Arvind Narula and Youji Company Limited (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on February 9, 2016)
|
|
10.69
|
Limited Liability Company Agreement of RBT – Youji, LLC, dated February 8, 2016 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on February 9, 2016)
|
|
10.70
|
Voting Agreement and Irrevocable Proxy, dated February 8, 2016, with Arvind Narula and Youji Company Limited (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on February 9, 2016)
|
|
10.71
|
Form of Securities Purchase Agreement, dated February 17, 2016 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on February 17, 2016)
|
|
10.72
|
Registration Rights Agreement, dated February 17, 2016 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on February 17, 2016)
|
|
10.73
|
Placement Agency Agreement, dated February 17, 2016 (incorporated herein by reference to exhibits previously filed on registrant’s current report on Form 8-K, filed on February 17, 2016)
|
|
Amendment to Loan, Guarantee and Security Agreement dated with Full Circle Capital Corporation, dated February 12, 2016 (filed herewith)
|
||
List of subsidiaries.
|
||
Consent of Independent Registered Public Accounting Firm.
|
||
Certification by CEO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
||
Certification by CFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
||
Certification by CEO and CFO pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
||
101.INS
|
@
|
XBRL Instance Document
|
101.SCH
|
@
|
XBRL Taxonomy Extension Schema Document
|
101.CAL
|
@
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.DEF
|
@
|
XBRL Taxonomy Extension Calculation Definition Linkbase Document
|
101.LAB
|
@
|
XBRL Taxonomy Extension Calculation Label Linkbase Document
|
101.PRE
|
@
|
XBRL Taxonomy Extension Calculation Presentation Linkbase Document
|
+ | Confidential treatment granted as to certain portions |
* | Indicates a management contract or compensatory plan, contract or arrangement in which any Director or any Executive Officer participates. |
@ | XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections. |
RICEBRAN TECHNOLOGIES
|
||
Date: March 30, 2016
|
By:
|
/s/ W. John Short
|
W. John Short
|
||
Director and Chief Executive Officer
|
Signature
|
Title
|
Date
|
||
Principal Executive Officer:
|
||||
/s/ W. John Short
|
Director and Chief Executive Officer
|
March 30, 2016
|
||
W. John Short
|
||||
Principal Financial Officer and
|
||||
Principal Accounting Officer
|
||||
/s/ J. Dale Belt
|
Chief Financial Officer and Secretary
|
March 30, 2016
|
||
Jerry Dale Belt
|
||||
Additional Directors:
|
||||
/s/ Marco V. Galante
|
Director
|
March 30, 2016
|
||
Marco V. Galante
|
||||
/s/ David Goldman
|
Director
|
March 30, 2016
|
||
David Goldman
|
||||
/s/ Baruch Halpern
|
Director
|
March 30, 2016
|
||
Baruch Halpern
|
||||
/s/ Henk W. Hoogenkamp
|
Director
|
March 30, 2016
|
||
Henk W. Hoogenkamp
|
||||
/s/ Robert C. Schweitzer
|
Director and Chairman
|
March 30, 2016
|
||
Robert C. Schweitzer
|
||||
/s/ Peter A. Woog
|
Director
|
March 30, 2016
|
||
Peter A. Woog
|
A. | The Grantors, the Lender and the Agent are parties to that certain Loan, Guarantee and Security Agreement dated as of May 12, 2015 (as amended from time to time, including the amendments effected pursuant to a Forbearance and Amendment Agreement (“Forbearance Agreement”) among the parties hereto, dated October 1, 2015, the “Loan Agreement”), pursuant to which the Agent and Lender extended a secured lending facility to the Borrower; and |
B. | Grantors acknowledge that the Borrower has informed the Agent that it anticipates to be in Default under Section 6 and Items 21(a), (b), (c) and (f) of the Schedule to the Loan Agreement for failure to comply with (i) the Total Debt to Adjusted EBITDA covenant for the periods ending March 31, 2016 and June 30, 2016 (ii) the Senior Debt to Adjusted EBITDA covenant for the periods ending March 31, 2016 and June 30, 2016, (iii) the Adjusted EBITDA to Fixed Charges covenant for the periods ending March 31, 2016 and June 30, 2016 , and (iv) Max Leverage Ratio for the quarters ending March 31, 2016 and June 30, 2016 (the “Potential Defaults”). |
C. | Grantors have requested that Agent and Lender (i) amend and waive certain provisions of the Loan Agreement in order to address the Potential Defaults and (ii) consent to the use of Borrower’s use of funds as provided herein; |
Section 1.
|
Recitals.
|
Section 2.
|
Use of Terms; Definitions.
|
Section 4.
|
Waiver of Financial Covenants
|
Section 5.
|
Amendments to the Loan Agreement.
|
Section 7.
|
Borrower Payments.
|
Section 8.
|
Acknowledgments.
|
Revolving Loan:
|
$
|
1,720,350.00
|
||
Term Loan:
|
$
|
2,500,000.00
|
Section 9.
|
Covenants, Representations and Acknowledgments of Grantors.
|
Section 11.
|
Reservation of Rights.
|
Section 12.
|
Miscellaneous
|
RICEBRAN TECHNOLOGIES
|
|
SRB-MT, LLC
|
||
|
|
|
|
|
By:
|
|
By:
|
|
|
Name:
|
|
Name:
|
|
|
Title:
|
|
Title:
|
|
|
|
|
|
|
|
NUTRACEA, LLC
|
|
SRB-WS, LLC
|
||
|
|
|
|
|
By:
|
|
|
By:
|
|
Name:
|
|
Name:
|
||
Title:
|
|
|
Title:
|
|
|
|
|
|
|
RICE RX, LLC
|
|
SRB-IP, LLC
|
||
|
|
|
|
|
By:
|
|
|
By:
|
|
Name:
|
|
|
Name:
|
|
Title:
|
|
|
Title:
|
|
|
|
|
|
|
RICE SCIENCE LLC
|
|
HEALTHY NATURAL, INC.
|
||
|
|
|
|
|
By:
|
|
|
By:
|
|
Name:
|
|
|
Name:
|
|
Title:
|
|
|
Title:
|
|
|
|
|
|
|
SRB-MERM, LLC
|
|
THE RICEX COMPANY
|
||
|
|
|
|
|
By:
|
|
|
By:
|
|
Name:
|
|
|
Name:
|
|
Title:
|
|
|
Title:
|
|
|
|
|
|
|
SRB-LC, LLC
|
|
RICEX NUTRIENT, INC.
|
||
|
|
|
|
|
By:
|
|
|
By:
|
|
Name:
|
|
|
Name:
|
|
Title:
|
|
Title:
|
|
AGENT AND LENDER
|
||
FULL CIRCLE CAPITAL CORPORATION
|
||
By:
|
/s/ Gregg J Felton | |
Name: Gregg J Felton
|
||
Title: President & CEO
|
Subsidiaries of the Registrant
|
State or Other Jurisdiction of Incorporation
|
Grain Enhancement, LLC (2) (6)
|
Delaware limited liability company
|
Nutra SA, LLC (3)
|
Delaware limited liability company
|
Healthy Natural Inc. (1)
|
Nevada
|
Industria Riograndens De Oleos Vegetais Ltda (4)
|
Limited liability company organized under the laws of the Federative Republic of Brazil
|
NutraCea, LLC (1)
|
Delaware limited liability company
|
RBT PRO, LLC (8)
|
Delaware limited liability company
|
RBT – YOUJI, LLC (9)
|
Delaware limited liability company
|
Rice Rx, LLC (1)
|
Delaware limited liability company
|
Rice Science LLC (1)
|
Delaware limited liability company
|
The RiceX Company (1)
|
Delaware corporation
|
RiceX Nutrients, Inc. (5)
|
Montana corporation.
|
SRB- MERM, LLC (7)
|
Delaware limited liability company
|
SRB-LC, LLC (7)
|
Delaware limited liability company
|
SRB-MT, LLC (7)
|
Delaware limited liability company
|
SRB-WS, LLC (7)
|
Delaware limited liability company
|
SRB- IP, LLC (7)
|
Delaware limited liability company
|
(1) | wholly owned subsidiary of RiceBran Technologies |
(2) | 47.5% interest |
(3) | 67.8% interest |
(4) | wholly owned subsidiary of Nutra SA, LLC |
(5) | wholly owned subsidiary of The RiceX Company |
(6) | inactive |
(7) | wholly owned subsidiary of NutraCea, LLC |
(8) | 50.0 % interest |
(9) | 55.0 % interest |
1) | I have reviewed this annual report on Form 10-K of RiceBran Technologies, a California corporation; |
2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4) | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report was prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5) | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ W. John Short
|
|
Name: W. John Short
|
|
Title: Chief Executive Officer
|
1) | I have reviewed this annual report on Form 10-K of RiceBran Technologies, a California corporation; |
2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4) | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report was prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5) | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ J. Dale Belt
|
|
Name: Jerry Dale Belt
|
|
Title: Chief Financial Officer
|
1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
By:
|
/s/ W. John Short
|
|
W. John Short
|
||
Chief Executive Officer
|
||
|
||
By:
|
/s/ J. Dale Belt
|
|
Jerry Dale Belt
|
||
Chief Financial Officer
|
Document and Entity Information - USD ($) |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2015 |
Mar. 30, 2016 |
Jun. 30, 2015 |
|
Document and Entity Information [Abstract] | |||
Entity Registrant Name | RiceBran Technologies | ||
Entity Central Index Key | 0001063537 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Public Float | $ 26,780,624 | ||
Entity Common Stock, Shares Outstanding | 10,487,415 | ||
Document Fiscal Year Focus | 2015 | ||
Document Fiscal Period Focus | FY | ||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2015 |
Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands |
12 Months Ended | |
---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Consolidated Statements of Comprehensive Loss [Abstract] | ||
Net loss | $ (10,576) | $ (26,627) |
Other comprehensive loss - foreign currency translation, net of tax | (2,573) | (1,404) |
Comprehensive loss, net of tax | (13,149) | (28,031) |
Comprehensive loss attributable to noncontrolling interest, net of tax | 3,147 | 4,081 |
Total comprehensive loss attributable to RiceBran Technologies shareholders | $ (10,002) | $ (23,950) |
LIQUIDITY, MANAGEMENT PLANS AND GENERAL BUSINESS |
12 Months Ended |
---|---|
Dec. 31, 2015 | |
LIQUIDITY, MANAGEMENT PLANS AND GENERAL BUSINESS [Abstract] | |
LIQUIDITY, MANAGEMENT PLANS AND GENERAL BUSINESS | NOTE 1. LIQUIDITY, MANAGEMENT PLANS AND GENERAL BUSINESS Liquidity and Management’s Plans In 2014 and 2015, we continued to experience losses and negative cash flows from operations which raises substantial doubt about our ability to continue as a going concern. We believe that we will be able to obtain additional funds to operate our business, should it be necessary, however, there can be no assurances that our efforts will prove successful. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. In January 2014, we completed the acquisition of Healthy Natural, Inc. (HN), the operations of which are accretive to cash flows. The Brazil segment consists of the consolidated operations of Nutra S.A. LLC (Nutra SA), whose only operating subsidiary is Industria Riograndens De Oleos Vegetais Ltda. (Irgovel), located in Pelotas, Brazil. Irgovel, completed the final stages of a major capital expansion during the first quarter of 2015. Throughout 2014, significant cash was used during the shutdown period and subsequent restart of the plant. In 2015 and 2014, we invested $3.6 million and $10.3 million in Nutra SA, to fund Irgovel working capital needs. Operations at Irgovel began to improve during the end of 2015, such that Irgovel should continue to improve its gross profit margins in 2016 subject to raw bran availability. However, there are no assurances that this will occur. In May 2015, we entered into an $8 million senior secured credit facility agreement with a lender (the Lender) consisting of a $3.5 million revolving loan, not to exceed a borrowing base, as defined in the agreement, and an initial $2.5 million term loan, which term loan may be increased at the Lender’s discretion by up to $2.0 million within 2 years. In February 2016, we issued and sold preferred stock and warrants that netted proceeds of $2.6 million. Funds received under the facility with the Lender and from the February offering are being used for working capital and capital expenditure needs in both of our operating segments. From January 1, 2016 through March 30, 2016, we have invested an additional $1.0 million in Nutra SA to fund Irgovel working capital needs. As of March 30, 2016, we may make additional investments in Nutra SA up to $0.5 million without prior approval of the Lender. In March 2016, the restricted cash previously held in a $1.9 million escrow account associated with the purchase of Irgovel (the status of which is discussed further in Note 14 to the consolidated financial statements) was released to us pursuant to a court order. We repaid $1.0 million of the term note with the Lender upon receipt of funds from the escrow account. General Business We are a human food ingredient, nutritional supplement and animal nutrition company focused on value-added processing and marketing of healthy, natural and nutrient dense products derived from raw rice bran an underutilized by-product of the rice milling industry. Using our bio-refining business model, we apply our proprietary and patented technologies and intellectual properties to convert raw rice bran into numerous high value products including stabilized rice bran (SRB), rice bran oil (RBO), defatted rice bran (DRB), RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a highly nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance, and ProRyza, rice bran protein-based products, and a variety of other valuable derivatives extracted from these core products. Our target markets are natural food, functional food, nutraceutical supplement and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally. We have two reportable operating segments: (i) USA segment, which manufactures and distributes SRB (for human food ingredient and animal nutrition customers) in various granulations along with Stage II products and derivatives and (ii) Brazil segment, which extracts crude RBO and DRB from rice bran, which are then further processed into fully refined rice bran oil for sale internationally and in Brazil, compounded animal nutrition products for horses, cows, swine, sheep and poultry and a number of valuable human food and animal nutrition products derivatives and co-products. Stage II refers to the proprietary processes run at our Dillon, Montana facility and includes products produced at that facility using our patented processes. In addition we incur corporate and other expenses not directly attributable to reportable operating segments, which include costs related to our corporate staff, general and administrative expenses including public company expenses, intellectual property, professional fees, and other expenses. No corporate allocations, including interest, are made to the reportable operating segments. The combined operations of our USA and Brazil segments encompass our bio-refining approach to processing raw rice bran into various high quality, value-added constituents and finished products. Over the past decade, we have developed and optimized our proprietary bio-refining processes to support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in human meats, baked goods, cereals, coatings, health foods, nutritional supplements, nutraceuticals and high-end animal nutrition and health products. The USA segment produces SRB inside two supplier rice mills in California and our facility in Mermentau, Louisiana. A facility located in Lake Charles, Louisiana has been idle since May 2009. The USA segment also includes our Dillon, Montana Stage II facility which produces our Stage II products: RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a highly nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance, and ProRyza, rice bran protein-based products, and a variety of other valuable derivatives extracted from these core products. The manufacturing facilities included in our USA segment have proprietary processing equipment and process patented technology for the stabilization and further processing of rice bran into finished products. In 2015, approximately 84% of USA segment revenue was from sales of human food products and the remainder was from sales of animal nutrition products. The Brazil segment consists of the consolidated operations of Nutra SA, whose only operating subsidiary is Irgovel, located in Pelotas, Brazil. Irgovel manufactures RBO and DRB products for both the human ingredient and animal nutrition markets in Brazil and internationally. In refining RBO to an edible grade, several co-products are obtained. One such product is distilled fatty acids, a valuable raw material for the detergent industry. Irgovel also produces rice lecithin, which has application in human nutrition, animal nutrition and industrial applications. DRB is compounded with a number of other ingredients to produce complex animal nutrition products which are packaged and sold under Irgovel brands in the Brazilian market, sold as a raw material for further processing into human food ingredients or sold in bulk into the animal nutrition markets in Brazil and neighboring countries. In 2015, approximately 52% of Brazil segment product revenue was from sales of RBO products and the remainder was from sales of DRB products. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
12 Months Ended |
---|---|
Dec. 31, 2015 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis or Presentation and Principles of Consolidation – The accompanying consolidated financial statements have been prepared in U.S. dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates. The accompanying consolidated financial statements include the accounts of RiceBran Technologies and all subsidiaries in which we have a controlling interest. Variable interest in subsidiaries for which we are the primary beneficiary are consolidated. All significant inter-company accounts and transactions are eliminated in consolidation. Noncontrolling interests in our subsidiaries are recorded net of tax as net earnings (loss) attributable to noncontrolling interests. Foreign Currencies and Currency Translation – The consolidated financial statements are presented in our reporting currency, U.S. Dollars. The functional currency for Irgovel is the Brazilian Real. Assets and liabilities of Irgovel are translated into U.S. Dollars using the exchange rate in effect at the consolidated balance sheet date. Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Irgovel’s revenues and expenses are translated using the average exchange rates in effect during the period. Translation differences are recorded in accumulated other comprehensive income (loss) as foreign currency translation. Gains or losses on transactions denominated in a currency other than Irgovel’s functional currency which arise as a result of changes in foreign exchange rates are recorded as foreign exchange gain or loss in the statements of operations. As of March 30, 2016, the Brazilian Real has fallen against the U.S. Dollar since December 31, 2015, by approximately 16%. The Brazilian Real exchange rate to the U.S. Dollar at December 31, 2013 was 0.4228, at December 31, 2014 it was 0.3758 and at December 31, 2015 it was 0.2523. Cash and Cash Equivalents – We consider all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December 31, 2015, we maintained our cash, including restricted cash, and cash equivalents, with major banks. We maintain cash in bank accounts in amounts which at times may exceed federally insured limits. We have not experienced any losses on such accounts. Accounts Receivable and Allowance for Doubtful Accounts – Accounts receivable represent amounts receivable on trade accounts. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts and the aging of accounts receivable. We analyze the aging of customer accounts, customer concentrations, customer credit-worthiness, current economic trends and changes in our customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts. From period to period, differences in judgments or estimates utilized may result in material differences in the amount and timing of the provision for doubtful accounts. We periodically evaluate our credit policy to ensure that the customers are worthy of terms and support our business plans. Inventories – Inventories are stated at the lower of cost or net realizable value, with cost determined by the first-in, first-out method. In the USA segment, we employ a full absorption procedure using standard cost techniques. The standards are customarily reviewed and adjusted annually so that they are materially consistent with actual purchase and production costs. In the Brazil segment we use actual average purchase and production costs. Provisions for potentially obsolete or slow moving inventory are made based upon our analysis of inventory levels, historical obsolescence and future sales forecasts; while inventory determined to be obsolete is written off immediately. Long-Lived Assets, Intangible Assets and Goodwill – Long-lived assets, consisting primarily of property, intangible assets, and goodwill, comprise a significant portion of our total assets. Property is stated at cost less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful lives. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains or losses on the sale of property and equipment are reflected in the consolidated statements of operations. Intangible assets are stated at cost less accumulated amortization and are amortized over their useful life on a straight-line or accelerated basis. We test goodwill and other indefinite-lived intangible assets for impairment on an annual basis or on an interim basis if an event occurs or circumstances change that may reduce the fair value of a reporting unit below its carrying value. Our annual qualitative or quantitative assessments involve determining an estimate of the fair value of our reporting units in order to evaluate whether an impairment of the current carrying amount of goodwill and other indefinite-lived intangible assets exists. A qualitative assessment evaluates whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount before applying the two-step quantitative goodwill impairment test. The first step of a quantitative goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired, and, thus, the second step of the quantitative impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the quantitative goodwill impairment test is performed to measure the amount of impairment loss, if any. Fair values are derived based on an evaluation of past and expected future performance of our reporting units. When we perform a quantitative estimate of fair value, we use level 3 inputs as defined by the fair value hierarchy. The inputs used to calculate the fair value include a number of subjective factors, such as estimates of future cash flows, estimates of our future cost structure, discount rates for our estimated cash flows, required level of working capital, assumed terminal value, and time horizon of cash flow forecasts. Estimating the fair value of an individual reporting unit requires us to make assumptions and estimates regarding our future plans, industry and economic conditions. We review our long-lived assets, which include intangible assets subject to amortization, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the undiscounted future cash flows estimated to be generated by the asset to be held and used are not sufficient to recover the unamortized balance of the asset. An impairment loss is recognized based on the difference between the carrying values and estimated fair value. The estimated fair value is determined based on either the discounted future cash flows or other appropriate fair value methods with the amount of any such deficiency charged to operations in the current year. Estimates of future cash flows are based on many factors, including current operating results, expected market trends and competitive influences. We also evaluate the amortization periods assigned to its intangible assets to determine whether events or changes in circumstances warrant revised estimates of useful lives. Assets to be disposed of by sale are reported at the lower of the carrying amount or fair value, less estimated costs to sell. Revenue Recognition – We recognize revenue for product sales when title and risk of loss pass to our customers, generally upon shipment for USA segment customers and Brazil segment international customers and upon customer receipt for Brazil segment domestic customers. Each transaction is evaluated to determine if all of the following four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the selling price is fixed and determinable; and (iv) collectability is reasonably assured. If any of the above criteria cannot be satisfied then such a transaction is not recorded as revenue, or is recorded as deferred revenue and recognized only when the sales cycle is complete and payment is either received or becomes reasonably assured. Changes in judgments and estimates regarding the application of the above mentioned four criteria might result in a change in the timing or amount of revenue recognized by such transactions. We make provisions for estimated returns, discounts and price adjustments when they are reasonably estimable. Revenues on the statements of operations are net of provisions for estimated returns, routine sales discounts, volume allowances and adjustments. Revenues on the statements of operations are also net of taxes collected from customers and remitted to governmental authorities. Amounts billed to a customer in a sale transaction related to shipping costs are reported as revenues and the related costs incurred for shipping are included in cost of goods sold. Research and Development – Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses. External expenses consist of costs associated with product development. All such costs are charged to expense in the period they are incurred. Derivative Warrant Liabilities – We have certain warrant agreements in effect that contain anti-dilution clauses. Under these clauses, we may be required to lower the exercise price on these warrants and issue additional warrants based on future issuances of our common stock and awards of options to employees, additional issuance of warrants and/or other convertible instruments below certain exercise prices. We account for the warrants with these anti-dilution clauses as liability instruments. These warrants are valued using the lattice model in each reporting period and the resultant change in fair value is recorded in the consolidated statements of operations in other income (expense). Share-Based Compensation – Share-based compensation expense for employees is calculated at the grant date using the Black-Scholes-Merton valuation model based on awards ultimately expected to vest, reduced for estimated forfeitures, and expensed on a straight-line basis over the service period of the grant. Forfeitures are estimated at the time of grant based on our historical forfeiture experience and are revised in subsequent periods if actual forfeitures differ from those estimates. The Black-Scholes-Merton option pricing model requires us to estimate key assumptions such as expected life, volatility, risk-free interest rates and dividend yield to determine the fair value of share-based awards, based on both historical information and management’s judgment regarding market factors and trends. We will use alternative valuation models if grants have characteristics that cannot be reasonably estimated using the Black-Scholes-Merton model. We account for share-based compensation awards granted to non-employees and consultants by determining the fair value of the awards granted at either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Generally we value options granted to non-employees and consultants using the Black-Scholes-Merton valuation model. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of (i) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The expense associated with stock awards issued to consultants or other third parties are recognized over the term of service. In the event services are terminated early or we require no specific future performance, the entire amount is expensed. The value is re-measured each reporting period over the requisite service period. Income Taxes – We account for income taxes by recording a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carryforwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for financial reporting and tax purposes during the year. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. A valuation allowance is established, when necessary, to reduce that deferred tax asset if it is more likely than not that the related tax benefits will not be realized. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations in Brazil. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that may be different from current estimates of the tax liabilities. If our estimate of tax liabilities proves to be less than the ultimate assessment, an additional charge to expense would result. If payment of these amounts ultimately proves to be less than the recorded amounts, the reversal of the liabilities may result in income tax benefits being recognized in the period when it is determined that the liabilities are no longer necessary. Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates. Reclassifications – Certain reclassifications have been made to amounts reported for the prior year to achieve consistent presentation with the current year. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers, to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and IFRS. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance is effective for our annual and interim periods beginning in 2018. Early adoption is permitted. We continue to assess the potential impact of the guidance. In February 2015, the FASB issued guidance which makes targeted amendments to current consolidation guidance. Among other things, the standard changes the manner in which we would assess one of the characteristics of variable interest entities (VIEs) and introduces a separate analysis specific to limited partnerships and similar entities (such as Nutra SA) for assessing if the equity holders at risk lack decision making. Limited partnerships and similar entities will be a VIE unless the limited partners hold substantive kick-out rights or participating rights. A right to liquidate an entity is akin to a kick-out right. Guidance for limited partnerships under the voting model has been eliminated. A limited partner and similar partners with a controlling financial interest obtained through substantive kick-out rights would consolidate a limited partnership or similar entity. The guidance is effective for our annual and interim periods beginning in 2016. Early adoption is allowed. The Company is in the process of determining the impact the new guidance will have on our results of operations and financial position and will determine if we will adopt the standard on a full or modified retrospective basis. In April 2015, the FASB issued guidance which requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset. We elected to early adopt these provisions effective October 1, 2015, retrospectively for all periods presented. As a result, $0.5 million of debt issuance costs as of December 31, 2015, are presented as a deduction of the related debt in these financial statements. There were no debt issuance costs included in our statement of financial statements as of December 31, 2014. In July 2015, the FASB issued an amendment which changes the measurement principle for inventory to the lower of cost and net realizable value. Entities are no longer to consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. We elected to early adopt these provisions prospectively effective October 1, 2015. Adoption had no impact on our results of operations. In November 2015, the FASB issued amendments which change the balance sheet classification of deferred income taxes. Previous standards required us to separate deferred income tax liabilities and assets into current and noncurrent amounts in our statements of financial position. The amendments require that deferred tax liabilities and assets be classified as noncurrent in our consolidated statements of financial position. As a result, each jurisdiction will now only have one net noncurrent deferred tax asset or liability. We elected to early adopt these provisions effective October 1, 2015, retrospectively to all periods presented. As a result, a $171 thousand deferred tax asset previously classified as current as of December 31, 2014, is classified as noncurrent, offsetting deferred tax liabilities in these consolidated financial statements. In February 2016, the FASB issued amendments which change the accounting for leases. As under prior GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on its classification as a finance or operating lease. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest on the lease liability. For operating leases, lessees will recognize a single total lease expense. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations and financial position and have not yet determined if we will early adopt the standard. |
LOSS PER SHARE (EPS) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LOSS PER SHARE (EPS) [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LOSS PER SHARE (EPS) | NOTE 3. LOSS PER SHARE (EPS) Basic EPS is computed by dividing net income (loss) attributable to RiceBran Technologies shareholders by the weighted average number of common shares outstanding during all periods presented. Shares underlying options and warrants and convertible instruments are excluded from the basic EPS calculation but are considered in calculating diluted EPS. Nonvested shares that vest solely on the basis of a service condition are not included in the denominator of the computation of basic EPS. Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies shareholders by the weighted average number of shares outstanding during the period increased by the number of additional shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effect of outstanding options and warrants is calculated using the treasury stock method. The dilutive effect of outstanding convertible instruments is calculated using the if-converted method. Nonvested shares that vest solely on the basis of a service condition are included in the denominator of the computation of diluted EPS during their requisite service period under the treasury stock method. Below are reconciliations of the numerators and denominators in the EPS computations.
The impacts of potentially dilutive securities outstanding at December 31, 2015 and 2014, were not included in the calculation of diluted EPS in 2015 and 2014 because to do so would be anti-dilutive. Those securities listed in the table above which were anti-dilutive in 2015 and 2014, which remain outstanding, could potentially dilute EPS in the future. |
HN ACQUISITION |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HN ACQUISITION [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HN ACQUISITION | NOTE 4. HN ACQUISITION In January 2014, we purchased all of the outstanding shares of HN for $2.0 million in cash ($1.8 million paid in January 2014 and $0.2 million payable upon the resolution of certain contingencies) and promissory notes in the face amount of $3.3 million, subject to working capital adjustments. HN is an Irving, Texas-based formulator and co-packer of products targeted at customers in the direct marketing, internet sales and retail distribution markets. HN serves the natural products, nutritional supplement and nutraceutical and functional food sectors. We acquired HN as part of our strategy to vertically integrate our business in order to leverage our proprietary and patented technologies. The acquisition has been accounted for as a business combination. The results of HN’s operations are included in our consolidated financial statements beginning January 2, 2014, and are included in our USA segment. In the first quarter of 2014, we incurred $0.3 million of acquisition-related costs which are included in selling, general and administrative expenses in the 2014 consolidated statement of operations. The following table summarizes the aggregate purchase price allocation, the consideration transferred to acquire HN, as well as the amounts of identified assets acquired and liabilities assumed based on the estimated fair value as of the January 2, 2014, acquisition date (in thousands).
The fair value of trade receivables at January 2, 2014, was $0.1 million which equaled the gross amount receivable. We assigned a $3.8 million value to a customer relationship intangible and we are amortizing that intangible over a three year period as follows: $1.7 million in 2014, $1.3 million in 2015 and $0.8 million in 2016. In 2015, we recognized $1.3 million of amortization expense in the USA segment related to this intangible. |
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA | NOTE 5. REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA We hold a variable interest which relates to our majority equity interest in Nutra SA, LLC (Nutra SA). We are the primary beneficiary of Nutra SA, and as such, Nutra SA’s assets, liabilities and results of operations are included in our consolidated financial statements. The other equity holders’ interests are reflected in net loss attributable to noncontrolling interest in Nutra SA, in the consolidated statements of operations, and redeemable noncontrolling interest in Nutra SA, in the consolidated balance sheets. Our variable interest in Nutra SA is our Brazil segment. A summary of the carrying amounts of Nutra SA balances included in our consolidated balance sheets follows (in thousands).
Nutra SA’s debt is secured by its accounts receivable and property. The non-Brazilian entities in our consolidated group do not guarantee any of Nutra SA’s debt. In December 2010, we entered into a membership interest purchase agreement (MIPA) with AF Bran Holdings-NL LLC and AF Bran Holdings LLC (Investors). The Investors’ share of Nutra SA’s net income (loss) increases (decreases) redeemable noncontrolling interest. We are restricted from competing with Nutra SA and Irgovel in Brazil as further described in the MIPA. In 2015 and 2014, we invested $3.6 million and $10.3 million in Nutra SA. From January 1, 2016 through March 30, 2016, we invested an additional $1.0 million in Nutra SA. As of March 30, 2016, we may make additional investments in Nutra SA up to $0.5 million without prior approval of the Lender. A summary of changes in redeemable noncontrolling interest and the Investor’s interest in Nutra SA follows (in thousands):
Redeemable noncontrolling interest in Nutra SA is recorded in temporary equity, above the equity section and after liabilities on our consolidated balance sheets, because the Investors have drag along rights which provide the Investors the ability to force a sale of Nutra SA assets in the future. We have assessed the likelihood of the Investors exercising these rights as less than probable at December 31, 2015. We will continue to evaluate the probability of the Investors exercising their drag along rights each reporting period. We will begin to accrete the redeemable noncontrolling interest up to fair value if and when it is probable the Investors will exercise these rights. Under the original limited liability company agreement for Nutra SA (LLC agreement), as amended, any units held by the Investors beginning January 1, 2014, accrued a yield at 4% (Yield). The LLC agreement was further amended in August 2015 to eliminate the Yield, which resulted in the reversal of the Yield accrued since January 1, 2014, in the amount of $0.5 million. Nutra SA must distribute all distributable cash (as defined in the LLC Agreement) to the members on March 31 of each year as follows: (i) first, to us and the Investors in proportion to our additional capital preference percentages (with respect to us, this means total contributions we make on or after June 3, 2015 as a percentage of the total contributions we make after June 3, 2015 plus the amount contributed by the investors as of April 30, 2015; with respect to the Investors, this means the amount contributed by the investors as of April 30, 2015, as a percentage of the amount contributed by the investors as of April 30, 2015, plus total contributions we make on or after June 3, 2015), (ii) second, to the Investors in an amount equal to 2.0 times the Investors’ capital contributions, less the aggregate amount of distributions paid to the Investors, (iii) third, to us in an amount equal to twice the capital contributions made by us, less the aggregate amount of distributions paid to us; and (iv) fourth, to us and the Investors in proportion to our respective membership interests. Under the LLC agreement, the business of Nutra SA is to be conducted by the manager, currently our CEO, subject to the oversight of the management committee. The management committee is comprised of three of our representatives and two Investor representatives. Upon an event of default or a qualifying event, we will no longer control the management committee and the management committee will include three Investor representatives and two of our representatives. In addition, following an event of default or a qualifying event, a majority of the members of the management committee may replace the manager of Nutra SA. As of December 31, 2015, there have been no unwaived events of default. Events of default, as defined in the MIPA and the October 2013 amendment of investment agreements, are failure of Irgovel to meet minimum annual processing targets or to achieve EBITDA on a local currency basis of at least R$4.0 million annually. As of December 31, 2015, there have been no qualifying events. The LLC agreement defines a qualifying event as the bankruptcy of RiceBran Technologies or Nutra SA. The Investors have drag along rights, the right to force the sale of all Nutra SA assets after January 1, 2018. The right terminates upon the occurrence of certain events (a $50 million Nutra SA initial public offering or a change of control, as defined). We may elect to exercise a right of first refusal to purchase the Investors’ interest instead of proceeding to a sale. In evaluating whether we are the primary beneficiary of Nutra SA, we considered the matters which could be put to a vote of the members. Until there is an event of default or a qualifying event, the Investors’ rights and abilities, individually or in the aggregate, do not allow them to substantively participate in the operations of Nutra SA. The Investors do not currently have the ability to dissolve Nutra SA or otherwise force the sale of all its assets. They do have drag along rights in the future. We will continue to evaluate our ability to control Nutra SA each reporting period. Cash provided by operations in our Brazil segment is generally unavailable for distribution to our Corporate and USA segments pursuant to the terms of the LLC agreement. |
CONCENTRATION OF RISK |
12 Months Ended |
---|---|
Dec. 31, 2015 | |
CONCENTRATION OF RISK [Abstract] | |
CONCENTRATION OF CREDIT RISK | NOTE 6. CONCENTRATION OF RISK Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of trade accounts receivable. We perform ongoing credit evaluations on our customers’ financial condition and generally do not require collateral. One USA segment customer accounted for approximately 31% of our revenues in 2015, 28% of our revenues in 2014, and 3% of our accounts receivable as of both December 31, 2015 and 2014. A second USA segment customer accounted for 2% of our sales in 2015, 1% of our sales in 2014, and 3% of our outstanding accounts receivable at both December 31, 2015 and 2014. A third USA segment customer, accounted for 1% of our sales in 2015 and 5% of our outstanding accounts receivable at December 31, 2015, less than 1% of our sales in 2014 and less than 1% of accounts receivable as of December 31, 2014. A fourth Brazil segment customer accounted for approximately 9% and 3% of our sales in 2015 and 2014 and approximately 17% and 22% of our accounts receivable at December 31, 2015 and 2014 As of December 31, 2015, 192 of our 264 employees were located in Brazil. All of our employees in Brazil are represented by a labor union and are covered by a collective bargaining agreement. At December 31, 2015, consolidated accounts receivable, net includes $1.0 million of Brazil segment accounts receivable. |
INVENTORIES |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORIES [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORIES | NOTE 7. INVENTORIES Inventories are composed of the following (in thousands):
|
PROPERTY |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROPERTY [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROPERTY | NOTE 8. PROPERTY Property consists of the following (in thousands):
Effective June 30, 2015, as a result of plant operational changes, Irgovel extended the estimated useful lives on its machinery and equipment from an average of 5 years to an average of 10 years. As a result, 2015 depreciation in cost of goods sold was approximately $0.3 million lower than it would have been prior to the change and loss per share was impacted favorably in 2015 by approximately $0.04 per share. |
INTANGIBLE ASSETS AND GOODWILL |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INTANGIBLE ASSETS AND GOODWILL [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INTANGIBLE ASSETS AND GOODWILL | NOTE 9. INTANGIBLE ASSETS AND GOODWILL Intangible assets consist of the following (in thousands):
Amortization expense was $1.5 million in the years ended December 31, 2015; expected to be $1.0 million in 2016, $0.1 million in 2017 and $0.1 million in 2018. Goodwill does not amortize. A summary of goodwill activity follows for 2015 and 2014.
We performed a quantitative analysis of our Brazil segment goodwill as of December 31, 2015. With the assistance of a valuation specialist, we calculated the net present value of Brazil segment estimated cash flows using a risk adjusted discount rate, in order to estimate the fair value of that reporting unit from the perspective of a market participant. We used discount rates and terminal growth rates of approximately 24% and 5%, respectively, to calculate the present value of estimated future cash flows. While the quantitative analysis indicated no impairment of Brazil segment goodwill existed as of December 31, 2015, if the future performance of that reporting unit falls short of our expectations or if there are significant changes in risk-adjusted discount rates due to changes in market conditions, we could be required to recognize material impairment charges in future periods. |
DEBT |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DEBT [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DEBT | NOTE 10. DEBT The following table summarizes current and long-term portions of debt as of December 31, 2015 and 2014 (in thousands):
Required future minimum payments on our debt as of December 31, 2015, follow (in thousands).
Corporate Segment Senior Revolving Loan and Term Note In May 2015, we entered into an $8 million senior secured credit facility agreement with a lender (the Lender) consisting of a $3.5 million revolving loan, not to exceed a borrowing base, as defined in the agreement, and an initial $2.5 million term loan, which term loan may be increased at the Lender’s discretion by up to $2.0 million within 2 years. The funds will be used for general corporate purposes and to provide working capital to facilitate future growth. The facility is secured by a senior interest in substantially all of our assets, excluding half of our interest in Nutra SA and RBT PRO, LLC. The credit facility matures on June 1, 2018, with the potential for two one-year maturity extensions. The loan bears interest at a variable interest rate based on LIBOR, with a 0.75% floor and 1.25% cap, plus 10.75% per annum, (11.5% at December 31, 2015) and we will pay certain fees under the agreement. Interest on the term loan is payable quarterly and principal payments of $0.1 million are payable quarterly beginning in October 2016 until the $1.4 million remainder is payable at maturity. We issued a warrant to purchase 300,000 shares of common stock (exercise price of $5.25, May 2020 expiration) to the Lender. As of December 31, 2015, the fair value of the warrant is $0.3 million. As of December 31, 2015, the remaining unamortized discount on the term note is $0.6 million. As of December 31, 2015, the remaining unamortized debt issuance costs related to the term note was $0.5 million. We accrete the term note up to its face value at an effective interest rate of 27.5% per year, 30.5% including amortization of debt issuance costs. The May 2015 agreement with the Lender included certain financial and non-financial covenants such as a requirement that we maintain $2.0 million of total liquidity at all times which is defined as $1.0 million in cash on hand and $1.0 million of available borrowings. In February 2016, we entered into an agreement with the Lender which modified the financial convents to require that (a) from February 1, 2016 to July 15, 2016, we maintain cash on hand, including availability under our revolving loan with the Lender, of not less than $1.5 million provided that at least $0.8 million of such amount must be in the form of cash on hand, and (b) we maintain an average monthly adjusted EBITDA, as defined by the agreement, calculated over each consecutive three-month period beginning on January 1, February 1, March 1, April 1 and May 1, 2016, of not less than $0.1 million. The Lender also waived, for the first two quarters of 2016, any non-compliance with the financial covenants in the May 2015 agreement. The amendment with the Lender requires that we repay $1.0 million of the senior term note which occurred on March 24, 2016. In consideration for the amendments, we paid and expensed $0.1 million to the Lender in 2016. Subordinated Notes In May 2015, the terms of subordinated notes in the principal amount of $6.3 million were amended to extend the maturity dates from July 2016 to May 2018 and change the interest rate from 5% per year to an annual interest rate of a rate determined as a function of LIBOR (as defined in the amendment) plus 11% (currently 11.75%) (the Note Amendment). Interest is payable quarterly. Principal is payable in seven quarterly installments of $0.3 million beginning in October 2016, with the remainder of principal due in May 2018. The holders of these notes received warrants to acquire 289,670 shares of common stock in the aggregate (exercise price of $5.25, May 2020 expiration). We accounted for the amendment as an extinguishment and reissuance. We recognized a $1.9 million loss on extinguishment equal to the total of (i) the difference between the $5.1 million carrying value of the notes on the date of the transaction and the $6.3 million face value of the notes and (ii) the $0.7 million fair value of the warrants at issuance. These notes are secured by a subordinated interest in substantially all of our assets, excluding our interest in Nutra SA and RBT PRO, LLC. The terms of subordinate notes in the principal amount of $0.2 million were not modified in May 2015. These notes bear an interest rate of 5% per year, payable quarterly, and mature in July 2016. We accrete these notes up to their face value at an effective interest rate of 24.5%. As of December 31, 2015, the remaining unamortized debt discount related to these notes was less than $0.1 million. These notes are secured by a subordinated interest in substantially all of our assets, excluding our interest in Nutra SA and RBT PRO, LLC. Brazil Segment All Brazil segment debt is denominated in the Brazilian Real (R$), except advances on customer export orders which are denominated in U.S. Dollars. Capital Expansion Loans In December 2011, Irgovel entered into loan agreements with the Bank of Brazil. As of December 31, 2015, the remaining notes held a principal balance of R$8.2 million. The annual interest rate on the loans is 6.5%, payable quarterly and the loans mature December 2021. Irgovel must make monthly principal payments under each of the loans. In July 2012, Irgovel entered into an agreement with the bank under which it borrowed R$1.7 million at an annual interest rate of 5.5%. Interest is payable quarterly on the amounts outstanding and the maturity date of the loans is July 2019. Irgovel must make monthly principal payments under the loans. The capital expansion loans are secured by the related equipment. Working Capital Lines of Credit Irgovel has working capital lines of credit secured by accounts receivable. The total amount of borrowing cannot exceed 40%-100% of the collateral, depending on the agreement. The annual interest rates on this debt range from 8.4% to 135.6%, and average 31.5%. Principal maturities of amounts outstanding extend through September 2017. Advances on Customer Export Orders Irgovel obtains advances against certain customer export orders from various banks. The annual interest rates on these advances range from 5.5% to 13.0%, and average 9.9%. Principal maturities of amounts outstanding extend through June 2016. Special Tax Programs Irgovel has an unsecured note payable for Brazilian federal and social security taxes under special Brazilian government tax programs. Principal and interest payments are due monthly through January 2029. Interest on the notes is payable monthly at the Brazilian SELIC target rate, which was 14.3% at December 31, 2015. Provisions and Covenants As of December 31, 2015, we are in compliance with the provisions and covenants associated with our debt agreements, as modified and discussed above. |
EQUITY AND SHARE-BASED COMPENSATION |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EQUITY AND SHARE-BASED COMPENSATION [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EQUITY AND SHARE-BASED COMPENSATION | NOTE 11. EQUITY AND SHARE-BASED COMPENSATION In February 2016, our board of directors authorized the issuance of 3,000 shares of Series F convertible preferred stock. The preferred stock is non-voting and may be converted into a total of 2,000,000 shares of our common stock at the holder’s election at any time, subject to certain beneficial ownership limitations, at a ratio of 1 preferred share for 666.66666 shares of common stock. The preferred stock is only entitled to receive dividends if we declare dividends, in which case the dividend will be paid (i) first an amount equal to $0.01 per share of preferred stock and (ii) then to and in the same form as dividends paid on shares of our common stock. Otherwise, the preferred stock has no liquidation or other preferences over our common stock. In May 2014, our shareholders approved an increase in our authorized shares of common stock from 6,000,000 shares to 25,000,000 shares. We have never declared or paid dividends on our common stock and have no plans to pay dividends in the foreseeable future. We are restricted from paying dividends or making other distributions to shareholders without prior approval from the Lender. Cash provided by operations in our Brazil segment is generally unavailable for distribution to our Corporate and USA segments pursuant to the terms of the limited liability company agreement for Nutra SA. Stock, Convertible Note and Warrant Offerings In January 2014, an underwriter exercised its overallotment rights related to our December 2013 secondary public offering. We issued and sold 162,586 shares of common stock for $5.24 per share and publicly traded warrants to purchase 162,586 shares of common stock ($6.55 per share exercise price and December 2018 expiration) for $0.01 per underlying share. In connection with the overallotment exercise, the underwriters for the offering also received a warrant for the purchase of 8,130 shares of common stock (exercise price of $6.55 per share and December 2018 expiration). The net proceeds from the overallotment exercise were $0.8 million, after deducting underwriting discounts and commissions and other cash offering expenses of $0.1 million, and are included in equity. We completed the first closing of a private placement offering in March 2014. We issued convertible notes in the principal amount of $4.9 million and warrants for the purchase of up to 1,399,614 shares of common stock ($5.25 per share exercise price and March 2019 expiration). We contributed $1.0 million of the $4.3 million proceeds, net of $0.6 million of costs, to Nutra SA, and used the remainder of the proceeds for capital projects in the United States and for general corporate purposes. On a fully diluted basis, at issuance we had available shares of common stock for 15.8% of the shares underlying the warrants. To the extent there were available shares, we allocated proceeds to equity for the warrants ($0.4 million). We recorded a derivative liability for the warrants to the extent there were not available shares ($5.0 million). We recorded $1.1 million in financing expense at closing representing the excess of the amounts recorded for the warrants over the net proceeds from the offering. The convertible notes issued in the offering were initially recorded with a discount equal to the face amount of the notes. As discussed below, in the Debt Conversions section, these notes converted in May 2014. We completed the second closing of the private placement offering in May 2014. We issued convertible notes in the principal amount of $1.2 million and warrants for the purchase of up to 357,075 shares of common stock, with an exercise price of $5.25 per share and a May 2019 expiration. We contributed $0.5 million of the $1.1 million proceeds, net of $0.2 million of costs, to Nutra SA, and used the remainder of the proceeds for capital projects in the United States and for general corporate purposes. On a fully diluted basis, at issuance we had no available shares of common stock for the shares underlying these warrants and, as a result, recorded a derivative liability for the fair value of these warrants at issuance ($2.0 million). We recorded $1.0 million in financing expense at closing, representing the excess of the amounts recorded for the warrants over the net proceeds from the offering. The convertible notes issued in the offering were initially recorded with a discount equal to the face amount of the notes. As discussed below, in the Debt Conversions section, these notes converted in May 2014. In June 2014, we issued and sold 1,417,500 shares of common stock for $5.29 per share and warrants to purchase 708,750 shares of common stock (exercise price of $5.87 per share and June 2019 expiration) for $0.01 per underlying share. The underwriters for the offering also received a warrant for the purchase of 85,050 shares of common stock (exercise price of $6.625 per share and June 2019 expiration). The net proceeds from the offering of $6.8 million, after deducting underwriting discounts and commissions and other cash offering expenses of $0.7 million, are included in common stock. We contributed $3.0 million of the proceeds to Nutra SA and used $0.8 million of the proceeds to pay all amounts due under the USA segment senior revolving note. In October 2014, we issued and sold 1,181,695 shares of common stock and warrants to purchase 1,181,695 shares of common stock (exercise price of $5.27 per share, exercisable beginning April 2015, April 2020 expiration) for $5.40 per unit, where a unit is one share of common stock and a warrant to purchase one share of common stock. The underwriters of the offering also received a warrant for the purchase of 94,536 shares of common stock (exercise price of $5.27 per share and October 2019 expiration). The net proceeds from the offering of $5.8 million, after deducting underwriting discounts and commissions and other estimated cash offering expenses of $0.6 million, are included in common stock. In February 2016, we issued and sold 3,000 shares of preferred stock for $1,000 per share, and sold warrants to purchase 2,660,000 shares of common stock (exercise price of $2.00 per share, exercisable beginning August 2016, April 2021 expiration). The underwriters of the offering also received a cash fee of $0.2 million. The net proceeds from the offering was $2.6 million, after deducting underwriting discounts and commissions and other estimated cash offering expenses of $0.4 million. As a result of this offering, we were required under our warrants that contain full ratchet anti-dilution provisions to reduce the exercise price on certain warrants from $5.24 per share to $1.50 per share and to increase the number of shares of common stock underlying these warrants from 426,489 shares to 1,489,868 shares. Debt Conversions In connection with the January 2014 acquisition of HN, we issued convertible promissory notes in the face amount of $3.3 million. The notes were due in equal quarterly payments commencing on March 31, 2015, and ending on December 31, 2018 and bore interest at 1% per year until January 2015, 5% per year from February 2015 until January 2016 and 10% per year after January 2016. We recorded the notes at their $2.2 million fair value and the conversion features at their $0.6 million fair value on the date of issuance. We accreted the notes at an effective interest rate of 18.9%, until the notes, and accumulated interest thereon, converted into 543,894 shares of common stock upon our issuance of shares to certain former warrant holders. The notes converted in May 2014. Upon conversion, we recognized a $0.9 million loss on extinguishment for the difference between the fair value of the shares issued ($3.9 million) and the carrying amount of the notes ($2.4 million) and related conversion feature ($0.6 million). The convertible notes issued in the March 2014 and May 2014 private placement closings, due in July 2016, bore interest at 5% interest until the $6.2 million outstanding on the notes, including accumulated interest thereon (less than $0.1 million), automatically converted in May 2014, at a conversion price of $5.25, into 1,180,567 shares of common stock upon shareholders voting to approve an increase in our authorized shares of common stock. When the notes converted, we recognized interest expense of $6.2 million, to accrete the notes to their face value, and increased equity $6.2 million. Warrants Reclassified to Equity Shares of available common stock increased in 2014 as a result of (i) the expiration of certain outstanding warrants and options and (ii) the 19,000,000 share increase in our authorized shares of common stock. As a result, during the second quarter of 2014, we transferred to equity the $8.9 million fair value of warrants previously classified as derivative liabilities solely due to a lack, on a fully-diluted basis, of available shares of common stock. Other Stock Issuances In February 2016, we issued 950,000 shares of common stock to a supplier. The shares are being held in escrow until earned (as defined in our agreement) by the supplier at a fixed price of $2.80 per share. While in escrow, the shares are subject to a voting agreement, pursuant to which the escrowed shares will be voted, or not voted, to match the vote of our other outstanding common stock on a pro rata percentage basis, in order to ensure no shareholder votes are impacted. In a 2013 transaction, we agreed to issue former warrant holders and a note holder 1,688,985 shares of our common stock. The shares were not required to be issued until after our shareholders approved an increase in our authorized shares of common stock, which occurred on May 30, 2014. Equity Incentive Plans, Options and Warrants A summary of stock option and warrant activity for 2015 and 2014 follows.
Our board of directors adopted our 2014 Equity Incentive Plan in August 2014 (2014 Plan), after the plan was approved by shareholders. A total of 1,600,000 shares of common stock were initially reserved for issuance under the plan. Under the terms of the plan, we may grant options to purchase common stock and shares of common stock to officers, directors, employees or consultants providing services on such terms as are determined by the board of directors. Our board of directors administers the plan, determines vesting schedules on plan awards and may accelerate the vesting schedules for award recipients. The options granted under the plan have terms of up to 10 years. As of December 31, 2015, options to purchase 241,239 shares have been issued and remain outstanding, 420,667 common shares have been issued and remain outstanding and 938,094 shares are reserved for future grants under the 2014 Plan. Our board of directors adopted our 2010 Equity Incentive Plan (2010 Plan) in February 2010. A total of 125,000 shares of common stock were initially reserved for issuance under the plan. The amount reserved increased annually each January 1st by 5% of the outstanding shares as of the prior December 31st. Additionally, in 2011 the board approved a 40,000 increase in the number of shares of common stock reserved under the plan. Under the terms of the 2010 Plan, we could grant options to purchase common stock and shares of common stock to officers, directors, employees or consultants providing services on such terms as are determined by the board of directors. Our board of directors administered the 2010 Plan, determined vesting schedules on plan awards and could accelerate the vesting schedules for award recipients. The options granted under the 2010 Plan have terms of up to 10 years. In 2013, the board of directors froze the 2010 Plan and there are no longer any shares reserved for future grants. Our board of directors adopted the 2005 Equity Incentive Plan (2005 Plan) in May 2005 and our shareholders approved the 2005 Plan in September 2005. Under the terms of the 2005 Plan, we could grant options to purchase common stock and shares of common stock to officers, directors, employees or consultants providing services on such terms as are determined by the board of directors. Options granted under the 2005 Plan have terms of up to 10 years. There are no longer any shares reserved for future grants under the 2005 Plan. Share-based compensation expenses related to option and stock grants issued to employees and directors are included in selling, general and administrative expenses in the statements of operations, and consisted of the following (in thousands):
In June 2015, we issued shares of common stock to directors and executive officers at a grant date fair value of $3.38 per share. We issued 67,003 shares which vest in equal annual installments over the next three years and 72,044 shares which vest in June 2016 (or at the next annual shareholder meeting date if earlier). In August 2014, we issued shares of common stock to directors and executive officers at a grant date fair value of $4.91 per share. We issued 44,026 shares which vested in August 2014, 52,412 shares which vested in June 2015 and 185,182 shares which vest in August 2017. In 2015, we recognized $0.6 million in compensation related to these issuances. As of December 31, 2015, we expect to recognize the remaining $0.8 million of unrecognized compensation for the nonvested shares over a weighted average period of 1.7 years. As of December 31, 2015, our outstanding options have no intrinsic value. The average fair value of options granted was $2.68 per share in 2015 and $4.29 per share in 2014. The following are the assumptions used in valuing stock options:
The following table summarizes information related to outstanding and exercisable options:
The following table summarizes equity and liability warrant activity during 2015 and 2014:
In addition to the warrants issued in connection with the offerings previously described in the Stock, Convertible Note and Warrant Offerings section, we issued the following:
The following table summarizes information related to outstanding and exercisable warrants:
|
EQUITY METHOD INVESTMENT |
12 Months Ended |
---|---|
Dec. 31, 2015 | |
EQUITY METHOD INVESTMENT [Abstract] | |
EQUITY METHOD INVESTMENT | NOTE 12. EQUITY METHOD INVESTMENT In 2013, we entered into a series of agreements with various affiliates of Wilmar International Limited (collectively Wilmar). In connection therewith, we sold a 50% membership interest in RBT PRO, LLC (RBT PRO) to Wilmar. RBT PRO granted a royalty free, perpetual sublicense of its license to use processes related to deriving protein from bran to Wilmar for exclusive use throughout China. We account for our investment in RBT PRO under the equity method. Any royalty revenue derived from that same license would be revenue of RBT PRO. Our investment in RBT PRO was zero as of December 31, 2015 and 2014, and RBT PRO has had no net income or loss since inception. We also entered into a cross license agreement with Wilmar, and under the agreements, we obtained rights to purchase a percentage of the capital stock of any entity Wilmar establishes to develop new products relating to rice bran or its derivative, as defined in the agreement, using the intellectual property licensed to Wilmar. |
INCOME TAXES |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INCOME TAXES [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INCOME TAXES | NOTE 13. INCOME TAXES Deferred tax assets (liabilities) are comprised of the following (in thousands):
Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. We have determined it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly we have provided a valuation allowance for deferred tax assets. Our valuation allowance is on U.S. and Brazil deferred tax assets. The change in valuation allowance of $2.0 million in 2015 was due to (i) $2.3 million in net operating loss and (ii) $0.1 million for the change in the valuation allowance against Brazil deferred tax assets, net of $1.6 million impact from foreign currency translation, offset by (i) the $0.1 million impact of net operating losses expiring and those being limited due to ownership changes (ii) $0.3 million of adjustments to stock compensation deferreds and other items. The change in valuation allowance of $47.1 million in 2014 was due to (i) $2.5 million in net operating loss and (ii) $3.0 million for the change in the valuation allowance against Brazil deferred tax assets, net of $0.6 million impact from foreign currency translation, offset by (i) the $41.8 million impact of net operating losses expiring and those being limited due to ownership changes (ii) $0.9 million from the impact of state rate changes (iii) $1.3 million from the establishment of deferred tax liabilities in the acquisition of HN (iv) $1.1 million of adjustments to intangibles and stock compensation deferreds, and (v) $7.5 million of adjustment to fixed asset deferred balance as a result of an accounting method change. As of December 31, 2015, net operating loss carryforwards for U.S. federal tax purposes totaled $10.0 million and expire at various dates from 2018 through 2035. Net operating loss carryforwards for state tax purposes totaled $13.6 million as of December 31, 2015, and expire at various dates from 2016 through 2035. As of December 31, 2015, net operating loss carryforwards for Brazil tax purposes totaled $12.7 million and do not expire but may be subject to substantial annual limitations (generally 30% of taxable income in any year). Due to offerings and conversions occurring between December 2013 and May 2014, we believe our ability to utilize previously accumulated net operating loss carryforwards are subject to substantial annual limitations due to “change in ownership” provisions of the Internal Revenue Code of 1986, as amended, and similar state regulations. Therefore in 2014, we recorded the impact of the expiration of substantial net operating loss carryforwards prior to utilization. We have not yet completed a formal analysis to determine the exact amount of such limitation, therefore, our estimate of the annual limitation is subject to change. We are subject to taxation in the U.S. and various states. We record liabilities for income tax contingencies based on our best estimate of the underlying exposures. We are open for audit by the IRS for years after 2012 and, generally, by U.S. state tax jurisdictions after 2011. We are open for audit by the Brazilian tax authorities for years after 2011. Loss before income taxes is comprised of the following (in thousands):
Foreign earnings are assumed to be permanently reinvested. U.S. federal income taxes have not been provided on undistributed earnings of our foreign subsidiary. The income tax benefit of $0.2 million in 2015 and $1.3 million in 2014 is all related to U.S. federal and state deferred tax benefit. Reconciliations between the amount computed by applying the U.S. federal statutory tax rate (34%) to loss before income taxes, and income tax benefit follows (in thousands):
We recognize interest and penalties related to uncertain tax positions in selling, general and administrative expenses. We have not identified any uncertain tax positions requiring a reserve as of December 31, 2015 or 2014. We may be subject to potential examination by various taxing authorities in the US and Brazil. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. We do not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. |
COMMITMENTS AND CONTINGENCIES |
12 Months Ended |
---|---|
Dec. 31, 2015 | |
COMMITMENTS AND CONTINGENCIES [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 14. COMMITMENTS AND CONTINGENCIES Employment Contracts We have entered into employment and other agreements with certain executives and other employees that provide for compensation and certain other benefits. These agreements provide for severance payments under certain circumstances. In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions. While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions. No amounts have been recorded in our financial statements with respect to any obligations under such agreements. Leases We lease certain properties under various operating lease arrangements that expire over the next twenty one years. These leases generally provide us with the option to renew the lease at the end of the lease term. Future minimum payments under these commitments as of December 31, 2015, are as follows: $0.7 million for 2016; $0.4 million in 2017; $0.3 million in 2018; $0.2 million in 2019; $0.1 million in 2020 and $0.8 million thereafter. We incurred rent expense of $0.7 million in 2015 and $0.8 million in 2014. Litigation In addition to the matters discussed below, from time to time we are involved in litigation incidental to the conduct of our business. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. Defense costs are expensed as incurred and are included in professional fees. Irgovel Purchase On August 28, 2008, former Irgovel stockholder David Resyng filed an indemnification suit against Irgovel, Osmar Brito and the remaining former Irgovel stockholders (Sellers), requesting: (i) the freezing of the escrow account maintained in connection with the transfer of Irgovel’s corporate control to us and the presentation of all documentation related to the transaction, and (ii) damages in the amount of the difference between (a) the sum received by David Resyng in connection with the judicial settlement agreement executed in the action for the partial dissolution of the limited liability company filed by David Resyng against Irgovel and the Sellers and (b) the amount received by the Sellers in connection with the sale of Irgovel’s corporate control to us, in addition to moral damages as determined in the court’s discretion. The amount of damage claimed by Mr. Resyng is approximately $3.0 million. We believe that the filing of the above lawsuit is a fundamental default of the obligations undertaken by the Sellers under the quotas purchase agreement for the transfer of Irgovel’s corporate control, executed by and among the Sellers and us on January 31, 2008 (Purchase Agreement). Consequently, we believe that the responsibility for any indemnity, costs and expenses incurred or that may come to be incurred by Irgovel and/or us in connection with the above lawsuit is the sole responsibility of the Sellers. On February 6, 2009, the Sellers filed a collection lawsuit against us seeking payment of the second installment of the purchase price under the Purchase Agreement, which the Sellers assert is approximately $1.0 million. We have withheld payment of the second installment pending resolution of the Resyng lawsuit noted above. Our parent company has not been served with any formal notices in regard to this matter. To date, only Irgovel has received formal legal notice. In addition, the Purchase Agreement requires that all disputes between us and the Sellers be adjudicated through arbitration. As part of the Purchase Agreement, $2.0 million was deposited into an escrow account to cover contingencies with the net remaining funds payable to the Sellers upon resolution of all contingencies. As of December 31, 2015, the balance in the escrow account was $1.9 million and is included in restricted cash in our balance sheets. On January 12, 2016, the US District Court for the District of Arizona entered a final judgment in our favor for a total of $1.9 million plus interest. On March 24, 2016, the $1.9 million in the escrow account was released to us to fund the award owed to us by the Sellers and, as required under an agreement with the Lender, we repaid $1.0 million of the term note with the Lender. We agreed to treat 90% of the funds retained from the escrow release as a distribution from Nutra SA and reduce our ownership percentage accordingly. As a result, our ownership percentage in Nutra SA reducecd .85%. in March 2016 when we received the escrow funds There is an escrow liability related to the lawsuit in accrued expenses on our balance sheets as of December 31, 2015 and 2014, totaling $1.9 million. When the escrow account was funded, we established an accrued liability equal to the amount of the escrow for contingencies and the net balance due to the Sellers under the terms of the Purchase Agreement. As of December 31, 2015, $0.3 million of pre-acquisition contingencies had either been paid or specifically identified and accrued, leaving a balance of $1.7 million to settle any remaining contingencies. We believe as of March 24, 2016, now that the escrow funds have been released to us, that there are no significant remaining contingencies. Irgovel - Events of Default As further described in Note 5, Irgovel is required to meet minimum annual processing targets or to achieve EBITDA on a local currency base of at least R$4.0 million annually. If not achieved, this would result in an event of default. It is possible that an event of default may be triggered and a waiver of non-compliance may not be obtained from the Investors. At December 31, 2015, Irgovel did not meet this covenant but Investors waived the requirement. |
RELATED PARTY TRANSACTIONS |
12 Months Ended |
---|---|
Dec. 31, 2015 | |
RELATED PARTY TRANSACTIONS [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 15. RELATED PARTY TRANSACTIONS Transactions with Baruch Halpern Entities beneficially owned by Baruch Halpern, a director, invested $2.6 million in our subordinated convertible notes and related warrants prior to 2014. In connection with the Note Amendment, in 2015, the notes, as previously modified, were amended to extend the maturity dates from July 2016 to May 2018 and change the interest rate from 5% per year to an annual interest rate of a rate determined as a function of LIBOR, consistent with other participating note holders. Entities beneficially owned by Mr. Halpern were also issued warrants to acquire 119,366 shares of common stock in the aggregate (exercise price of $5.25, May 2020 expiration). We recognized a loss on extinguishment in 2015 related to the amendment of notes beneficially owned by Mr. Halpern. We recognized a loss on extinguishment in 2015 related to this transaction of $0.7 million. We paid and expensed interest on subordinated notes beneficially owned by Mr. Halpern totaling $0.2 million in 2015 and $0.1 million in 2014. In a 2013 transaction, warrants beneficially owned by Mr. Halpern for the purchase of up to 231,397 shares of common stock were cancelled in exchange for 710,056 shares of our common stock. The shares were not required to be issued until after our shareholders approved an increase in our authorized shares of common stock, which occurred on May 30, 2014. In January 2016, we entered into a note payable with Mr. Halpern in the principal amount of $0.3 million and issued Mr. Halpern warrants to acquire 25,000 share of common stock (exercise price of $5.25, January 2021 expiration). Principal and all interest, accumulating at an 11.75% annual rate, was payable October 31, 2016. We paid the note and accumulated interest in full in March 2016. Transactions with W. John Short W. John Short, our chief executive officer and director, invested in $50 thousand of our subordinated notes and related warrants prior to 2014. In connection with the Note Amendment, in 2015, the notes, as previously modified, were amended to extend the maturity dates from July 2016 to May 2018 and change the interest rate from 5% per year to an annual interest rate of a rate determined as a function of LIBOR, consistent with other participating note holders. Mr. Short was also issued warrants to acquire 2,446 shares of common stock in the aggregate (exercise price of $5.25, May 2020 expiration). In 2015 and 2014, we paid and expensed less than $10 thousand of interest on subordinated notes beneficially owned by Mr. Short. In a 2013 transaction, warrants beneficially owned by Mr. Short for the purchase of up to 3,806 shares of common stock were cancelled in exchange for 12,777 shares of our common stock. The shares were not required to be issued until after our shareholders approved an increase in our authorized shares of common stock, which occurred on May 30, 2014. Transactions with Mark McKnight In January 2014, we purchased all of the outstanding shares of HN for $2.0 million in cash, plus convertible promissory notes for $3.3 million. Mark McKnight, our current senior vice president of sales, and his wife collectively owned a majority interest in HN prior to the acquisition. In connection with our acquisition of HN, Mark McKnight received $0.7 million in cash and a convertible promissory note for $1.4 million and Nicole McKnight, his wife, received $0.7 million in cash and a convertible promissory note for $1.4 million. We had the option to pay principal and accrued interest under the notes in either cash or in our common stock, however, if we issued shares to certain former warrants holders upon an increase in authorized shares we were required to settle any outstanding balance on the notes through the issuance of shares of our common stock. On May 30, 2014, we issued 225,925 shares of common stock to settle Mark McKnight’s note and 225,925 shares of common stock to settle Nicole McKnight’s note. The notes were converted at a conversion price of $6.00 per share. In January 2014, we entered into a $0.1 million, 5% unsecured, promissory note with Nicole McKnight. We paid all principal and interest due under the note in October 2014. |
SEGMENT INFORMATION |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SEGMENT INFORMATION [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SEGMENT INFORMATION | NOTE 16. SEGMENT INFORMATION We have two reportable operating segments in all periods presented: (i) USA segment, which manufactures and distributes SRB in various granulations along with Stage II products and derivatives and (ii) Brazil segment, which extracts crude RBO and DRB from rice bran, which are then further processed into fully refined rice bran oil for sale internationally and in Brazil, compounded animal nutrition products for horses, cows, swine, sheep and poultry and a number of valuable human food and animal nutrition products derivatives and co-products. In addition we incur corporate and other expenses not directly attributable to operating segments, which include costs related to our corporate staff, general and administrative expenses including public company expenses, intellectual property, professional fees, and other expenses. No Corporate allocations, including interests, are made to the operating segments. The table below presents segment information for the years identified and provides a reconciliation of segment information to total consolidated information (in thousands).
The following table presents revenues data by geographic area shipped to (in thousands):
|
FAIR VALUE MEASUREMENT |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FAIR VALUE MEASUREMENT [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FAIR VALUE MEASUREMENT | NOTE 17. FAIR VALUE MEASUREMENT The fair value of cash and cash equivalents, accounts and other receivables and accounts payable approximates their carrying value due to their shorter maturities. As of December 31, 2015, the fair value of our Corporate segment debt (Level 3 measurement) is approximately $0.1 million lower than the $9.7 million carrying value of that debt, based on current market rates for similar debt with similar maturities. The fair value of our Brazil segment debt (Level 3 measurement) approximates the $6.3 million carrying value of that debt based on the current market rates for similar debt with similar maturities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Certain assets and liabilities are presented in the financial statements at fair value. Assets and liabilities measured at fair value on a recurring basis include derivative warrant and conversion liabilities. Assets and liabilities measured at fair value on a non-recurring basis may include property. We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market:
For instruments measured using Level 3 inputs, a reconciliation of the beginning and ending balances is disclosed. The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our consolidated balance sheets (in thousands):
Warrants accounted for as derivative liabilities are valued using the lattice model each reporting period and the resultant change in fair value is recorded in the statements of operations. The lattice model requires us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants. The risk-free interest rate is determined by reference to the treasury yield curve rate of instruments with the same term as the warrant. Additional assumptions that were used to calculate fair value follow.
The following tables summarize the changes in level 3 items measured at fair value on a recurring basis (in thousands):
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) |
12 Months Ended |
---|---|
Dec. 31, 2015 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract] | |
Basis or Presentation and Principles of Consolidation | Basis or Presentation and Principles of Consolidation – The accompanying consolidated financial statements have been prepared in U.S. dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates. The accompanying consolidated financial statements include the accounts of RiceBran Technologies and all subsidiaries in which we have a controlling interest. Variable interest in subsidiaries for which we are the primary beneficiary are consolidated. All significant inter-company accounts and transactions are eliminated in consolidation. Noncontrolling interests in our subsidiaries are recorded net of tax as net earnings (loss) attributable to noncontrolling interests. |
Foreign Currencies and Currency Translation | Foreign Currencies and Currency Translation – The consolidated financial statements are presented in our reporting currency, U.S. Dollars. The functional currency for Irgovel is the Brazilian Real. Assets and liabilities of Irgovel are translated into U.S. Dollars using the exchange rate in effect at the consolidated balance sheet date. Equity accounts are translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Irgovel’s revenues and expenses are translated using the average exchange rates in effect during the period. Translation differences are recorded in accumulated other comprehensive income (loss) as foreign currency translation. Gains or losses on transactions denominated in a currency other than Irgovel’s functional currency which arise as a result of changes in foreign exchange rates are recorded as foreign exchange gain or loss in the statements of operations. As of March 30, 2016, the Brazilian Real has fallen against the U.S. Dollar since December 31, 2015, by approximately 16%. The Brazilian Real exchange rate to the U.S. Dollar at December 31, 2013 was 0.4228, at December 31, 2014 it was 0.3758 and at December 31, 2015 it was 0.2523. |
Cash and Cash Equivalents | Cash and Cash Equivalents – We consider all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December 31, 2015, we maintained our cash, including restricted cash, and cash equivalents, with major banks. We maintain cash in bank accounts in amounts which at times may exceed federally insured limits. We have not experienced any losses on such accounts. |
Accounts Receivable and Allowance for Doubtful Accounts | Accounts Receivable and Allowance for Doubtful Accounts – Accounts receivable represent amounts receivable on trade accounts. The allowance for doubtful accounts is based on our assessment of the collectability of customer accounts and the aging of accounts receivable. We analyze the aging of customer accounts, customer concentrations, customer credit-worthiness, current economic trends and changes in our customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts. From period to period, differences in judgments or estimates utilized may result in material differences in the amount and timing of the provision for doubtful accounts. We periodically evaluate our credit policy to ensure that the customers are worthy of terms and support our business plans. |
Inventories | Inventories – Inventories are stated at the lower of cost or net realizable value, with cost determined by the first-in, first-out method. In the USA segment, we employ a full absorption procedure using standard cost techniques. The standards are customarily reviewed and adjusted annually so that they are materially consistent with actual purchase and production costs. In the Brazil segment we use actual average purchase and production costs. Provisions for potentially obsolete or slow moving inventory are made based upon our analysis of inventory levels, historical obsolescence and future sales forecasts; while inventory determined to be obsolete is written off immediately. |
Long-Lived Assets, Intangible Assets and Goodwill | Long-Lived Assets, Intangible Assets and Goodwill – Long-lived assets, consisting primarily of property, intangible assets, and goodwill, comprise a significant portion of our total assets. Property is stated at cost less accumulated depreciation. Depreciation is computed on the straight-line basis over the estimated useful lives. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains or losses on the sale of property and equipment are reflected in the consolidated statements of operations. Intangible assets are stated at cost less accumulated amortization and are amortized over their useful life on a straight-line or accelerated basis. We test goodwill and other indefinite-lived intangible assets for impairment on an annual basis or on an interim basis if an event occurs or circumstances change that may reduce the fair value of a reporting unit below its carrying value. Our annual qualitative or quantitative assessments involve determining an estimate of the fair value of our reporting units in order to evaluate whether an impairment of the current carrying amount of goodwill and other indefinite-lived intangible assets exists. A qualitative assessment evaluates whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount before applying the two-step quantitative goodwill impairment test. The first step of a quantitative goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not considered impaired, and, thus, the second step of the quantitative impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the quantitative goodwill impairment test is performed to measure the amount of impairment loss, if any. Fair values are derived based on an evaluation of past and expected future performance of our reporting units. When we perform a quantitative estimate of fair value, we use level 3 inputs as defined by the fair value hierarchy. The inputs used to calculate the fair value include a number of subjective factors, such as estimates of future cash flows, estimates of our future cost structure, discount rates for our estimated cash flows, required level of working capital, assumed terminal value, and time horizon of cash flow forecasts. Estimating the fair value of an individual reporting unit requires us to make assumptions and estimates regarding our future plans, industry and economic conditions. We review our long-lived assets, which include intangible assets subject to amortization, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the undiscounted future cash flows estimated to be generated by the asset to be held and used are not sufficient to recover the unamortized balance of the asset. An impairment loss is recognized based on the difference between the carrying values and estimated fair value. The estimated fair value is determined based on either the discounted future cash flows or other appropriate fair value methods with the amount of any such deficiency charged to operations in the current year. Estimates of future cash flows are based on many factors, including current operating results, expected market trends and competitive influences. We also evaluate the amortization periods assigned to its intangible assets to determine whether events or changes in circumstances warrant revised estimates of useful lives. Assets to be disposed of by sale are reported at the lower of the carrying amount or fair value, less estimated costs to sell. |
Revenue Recognition | Revenue Recognition – We recognize revenue for product sales when title and risk of loss pass to our customers, generally upon shipment for USA segment customers and Brazil segment international customers and upon customer receipt for Brazil segment domestic customers. Each transaction is evaluated to determine if all of the following four criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the selling price is fixed and determinable; and (iv) collectability is reasonably assured. If any of the above criteria cannot be satisfied then such a transaction is not recorded as revenue, or is recorded as deferred revenue and recognized only when the sales cycle is complete and payment is either received or becomes reasonably assured. Changes in judgments and estimates regarding the application of the above mentioned four criteria might result in a change in the timing or amount of revenue recognized by such transactions. We make provisions for estimated returns, discounts and price adjustments when they are reasonably estimable. Revenues on the statements of operations are net of provisions for estimated returns, routine sales discounts, volume allowances and adjustments. Revenues on the statements of operations are also net of taxes collected from customers and remitted to governmental authorities. Amounts billed to a customer in a sale transaction related to shipping costs are reported as revenues and the related costs incurred for shipping are included in cost of goods sold. |
Research and Development | Research and Development – Research and development expenses include internal and external costs. Internal costs include salaries and employment related expenses. External expenses consist of costs associated with product development. All such costs are charged to expense in the period they are incurred. |
Derivative Warrant Liabilities | Derivative Warrant Liabilities – We have certain warrant agreements in effect that contain anti-dilution clauses. Under these clauses, we may be required to lower the exercise price on these warrants and issue additional warrants based on future issuances of our common stock and awards of options to employees, additional issuance of warrants and/or other convertible instruments below certain exercise prices. We account for the warrants with these anti-dilution clauses as liability instruments. These warrants are valued using the lattice model in each reporting period and the resultant change in fair value is recorded in the consolidated statements of operations in other income (expense). |
Share-Based Compensation | Share-Based Compensation – Share-based compensation expense for employees is calculated at the grant date using the Black-Scholes-Merton valuation model based on awards ultimately expected to vest, reduced for estimated forfeitures, and expensed on a straight-line basis over the service period of the grant. Forfeitures are estimated at the time of grant based on our historical forfeiture experience and are revised in subsequent periods if actual forfeitures differ from those estimates. The Black-Scholes-Merton option pricing model requires us to estimate key assumptions such as expected life, volatility, risk-free interest rates and dividend yield to determine the fair value of share-based awards, based on both historical information and management’s judgment regarding market factors and trends. We will use alternative valuation models if grants have characteristics that cannot be reasonably estimated using the Black-Scholes-Merton model. We account for share-based compensation awards granted to non-employees and consultants by determining the fair value of the awards granted at either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Generally we value options granted to non-employees and consultants using the Black-Scholes-Merton valuation model. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of (i) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty's performance is complete. The expense associated with stock awards issued to consultants or other third parties are recognized over the term of service. In the event services are terminated early or we require no specific future performance, the entire amount is expensed. The value is re-measured each reporting period over the requisite service period. |
Income Taxes | Income Taxes – We account for income taxes by recording a deferred tax asset or liability for the recognition of future deductible or taxable amounts and operating loss and tax credit carryforwards. Deferred tax expense or benefit is recognized as a result of timing differences between the recognition of assets and liabilities for financial reporting and tax purposes during the year. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. A valuation allowance is established, when necessary, to reduce that deferred tax asset if it is more likely than not that the related tax benefits will not be realized. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations in Brazil. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that may be different from current estimates of the tax liabilities. If our estimate of tax liabilities proves to be less than the ultimate assessment, an additional charge to expense would result. If payment of these amounts ultimately proves to be less than the recorded amounts, the reversal of the liabilities may result in income tax benefits being recognized in the period when it is determined that the liabilities are no longer necessary. |
Use of Estimates | Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Because of the uncertainty inherent in such estimates, actual results could differ from those estimates. |
Reclassifications | Reclassifications – Certain reclassifications have been made to amounts reported for the prior year to achieve consistent presentation with the current year. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers, to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and IFRS. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance is effective for our annual and interim periods beginning in 2018. Early adoption is permitted. We continue to assess the potential impact of the guidance. In February 2015, the FASB issued guidance which makes targeted amendments to current consolidation guidance. Among other things, the standard changes the manner in which we would assess one of the characteristics of variable interest entities (VIEs) and introduces a separate analysis specific to limited partnerships and similar entities (such as Nutra SA) for assessing if the equity holders at risk lack decision making. Limited partnerships and similar entities will be a VIE unless the limited partners hold substantive kick-out rights or participating rights. A right to liquidate an entity is akin to a kick-out right. Guidance for limited partnerships under the voting model has been eliminated. A limited partner and similar partners with a controlling financial interest obtained through substantive kick-out rights would consolidate a limited partnership or similar entity. The guidance is effective for our annual and interim periods beginning in 2016. Early adoption is allowed. The Company is in the process of determining the impact the new guidance will have on our results of operations and financial position and will determine if we will adopt the standard on a full or modified retrospective basis. In April 2015, the FASB issued guidance which requires debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the related debt liability instead of being presented as an asset. We elected to early adopt these provisions effective October 1, 2015, retrospectively for all periods presented. As a result, $0.5 million of debt issuance costs as of December 31, 2015, are presented as a deduction of the related debt in these financial statements. There were no debt issuance costs included in our statement of financial statements as of December 31, 2014. In July 2015, the FASB issued an amendment which changes the measurement principle for inventory to the lower of cost and net realizable value. Entities are no longer to consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. We elected to early adopt these provisions prospectively effective October 1, 2015. Adoption had no impact on our results of operations. In November 2015, the FASB issued amendments which change the balance sheet classification of deferred income taxes. Previous standards required us to separate deferred income tax liabilities and assets into current and noncurrent amounts in our statements of financial position. The amendments require that deferred tax liabilities and assets be classified as noncurrent in our consolidated statements of financial position. As a result, each jurisdiction will now only have one net noncurrent deferred tax asset or liability. We elected to early adopt these provisions effective October 1, 2015, retrospectively to all periods presented. As a result, a $171 thousand deferred tax asset previously classified as current as of December 31, 2014, is classified as noncurrent, offsetting deferred tax liabilities in these consolidated financial statements. In February 2016, the FASB issued amendments which change the accounting for leases. As under prior GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease for us as a lessee depend primarily on its classification as a finance or operating lease. For capital or finance leases, lessees will recognize amortization of the right-of-use asset separately from interest on the lease liability. For operating leases, lessees will recognize a single total lease expense. For both types of leases, lessees will recognize a right-of-use asset and a lease liability. The guidance is effective for our annual and interim periods beginning in 2019 and must be adopted on a modified retrospective approach. Early adoption is allowed. We have not yet determined the impact that the new guidance will have on our results of operations and financial position and have not yet determined if we will early adopt the standard. |
LOSS PER SHARE (EPS) (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LOSS PER SHARE (EPS) [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of EPS computations | Below are reconciliations of the numerators and denominators in the EPS computations.
|
HN ACQUISITION (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HN ACQUISITION [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of aggregate purchase price allocation | The following table summarizes the aggregate purchase price allocation, the consideration transferred to acquire HN, as well as the amounts of identified assets acquired and liabilities assumed based on the estimated fair value as of the January 2, 2014, acquisition date (in thousands).
|
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REDEEMABLE NONCONTROLLING INTEREST IN NUTRA SA [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of the carrying amounts included in consolidated balance sheets | A summary of the carrying amounts of Nutra SA balances included in our consolidated balance sheets follows (in thousands).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of changes in redeemable noncontrolling interest | A summary of changes in redeemable noncontrolling interest and the Investor’s interest in Nutra SA follows (in thousands):
|
INVENTORIES (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INVENTORIES [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories are composed of the following (in thousands):
|
PROPERTY (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROPERTY [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property | Property consists of the following (in thousands):
|
INTANGIBLE ASSETS AND GOODWILL (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INTANGIBLE ASSETS AND GOODWILL [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intangible assets | Intangible assets consist of the following (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of goodwill activity | A summary of goodwill activity follows for 2015 and 2014.
|
DEBT (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DEBT [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Current and long-term debt | The following table summarizes current and long-term portions of debt as of December 31, 2015 and 2014 (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Required future minimum payments on debt | Required future minimum payments on our debt as of December 31, 2015, follow (in thousands).
|
EQUITY AND SHARE-BASED COMPENSATION (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EQUITY AND SHARE-BASED COMPENSATION [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of stock option and warrant activity | A summary of stock option and warrant activity for 2015 and 2014 follows.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based compensation expenses included in selling, general and administrative expenses | Share-based compensation expenses related to option and stock grants issued to employees and directors are included in selling, general and administrative expenses in the statements of operations, and consisted of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Weighted-average assumptions used in valuing stock options | The following are the assumptions used in valuing stock options:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of information related to outstanding and exercisable options | The following table summarizes information related to outstanding and exercisable options:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of warrant activity | The following table summarizes equity and liability warrant activity during 2015 and 2014:
In addition to the warrants issued in connection with the offerings previously described in the Stock, Convertible Note and Warrant Offerings section, we issued the following:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of information related to outstanding and exercisable warrants | The following table summarizes information related to outstanding and exercisable warrants:
|
INCOME TAXES (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INCOME TAXES [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deferred tax assets and liabilities | Deferred tax assets (liabilities) are comprised of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss from continuing operations before income taxes | Loss before income taxes is comprised of the following (in thousands):
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effective income tax rate reconciliation | Reconciliations between the amount computed by applying the U.S. federal statutory tax rate (34%) to loss before income taxes, and income tax benefit follows (in thousands):
|
SEGMENT INFORMATION (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SEGMENT INFORMATION [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment information identified and reconciliations of segment information to total consolidated information | The table below presents segment information for the years identified and provides a reconciliation of segment information to total consolidated information (in thousands).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Revenues by geographic area | The following table presents revenues data by geographic area shipped to (in thousands):
|
FAIR VALUE MEASUREMENT (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FAIR VALUE MEASUREMENT [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair values by input hierarchy of items measured at fair value on a recurring basis | The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our consolidated balance sheets (in thousands):
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional assumptions used to calculate fair value | Additional assumptions that were used to calculate fair value follow.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Changes in level 3 items measured at fair value | The following tables summarize the changes in level 3 items measured at fair value on a recurring basis (in thousands):
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) $ in Thousands |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2014
USD ($)
|
Dec. 31, 2013 |
|
Foreign Currencies and Currency Translation [Abstract] | |||
Percentage of decrease in value of foreign currency | 16.00% | ||
Brazilian Real exchange rate to U.S. Dollar | 0.2523 | 0.3758 | 0.4228 |
Recent Accounting Pronouncements [Abstract] | |||
Debt issuance cost | $ 500 | $ 0 | |
Deferred tax asset | $ 171 |
INVENTORIES (Details) - USD ($) $ in Thousands |
Dec. 31, 2015 |
Dec. 31, 2014 |
---|---|---|
INVENTORIES [Abstract] | ||
Finished goods | $ 1,575 | $ 1,103 |
Work in process | 270 | 380 |
Raw materials | 1,259 | 1,441 |
Packaging supplies | 753 | 584 |
Total inventories | $ 3,857 | $ 3,508 |
EQUITY METHOD INVESTMENT (Details) |
12 Months Ended |
---|---|
Dec. 31, 2013 | |
EQUITY METHOD INVESTMENT [Abstract] | |
Ownership interest sold | 50.00% |
INCOME TAXES (Details) - USD ($) $ in Thousands |
12 Months Ended | |
---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
United States [Abstract] | ||
Net operating loss carryforwards | $ 4,007 | $ 2,503 |
Gain on sale of membership interests in Nutra SA | 366 | 369 |
Stock options and warrants | 719 | 625 |
Property | (174) | (80) |
Intangible assets | (274) | (797) |
Capitalized expenses | 462 | 525 |
Debt and deferred financing | 329 | (116) |
Other | 345 | 642 |
Deferred tax assets | 5,780 | 3,671 |
Less: Valuation allowance | (5,814) | (3,896) |
Deferred tax asset (liability) | (34) | (225) |
Brazil [Abstract] | ||
Property | (731) | (1,141) |
Intangible assets | 0 | (28) |
Net operating loss carryforwards | 4,320 | 4,666 |
Other | 360 | 370 |
Net deferred tax asset (liability) | 3,949 | 3,867 |
Less: valuation allowance | (3,949) | (3,867) |
Deferred tax asset (liability) | 0 | 0 |
Change in valuation allowance | 2,000 | 47,100 |
Change in net operating loss and other deferred changes | 2,300 | 2,500 |
Impact of adjustments to capitalized expenses and stock option compensation | 300 | 1,100 |
Operating Loss Carryforwards [Line Items] | ||
Impact of foreign currency translation | 1,600 | 600 |
Loss before income taxes [Abstract] | ||
Foreign | (5,136) | (10,504) |
Domestic | (5,616) | (17,427) |
Loss before income taxes | $ (10,752) | $ (27,931) |
Federal statutory income tax rate | 34.00% | 34.00% |
Income Tax Reconciliation [Abstract] | ||
Income tax benefit at federal statutory rate | $ (3,656) | $ (9,496) |
Increase (decrease) resulting from: [Abstract] | ||
State tax benefit, net of federal tax effect | (176) | (206) |
Change in valuation allowance | 3,601 | (46,511) |
Expiration of U.S. net operating losses | 101 | 41,756 |
Adjustment to fixed asset deferred balance | 0 | 7,450 |
Adjustment to intangible deferred balances | 0 | 484 |
Reduction in deferred balances for forfeited, expired or cancelled options | 75 | 597 |
Nontaxable fair value adjustment | (340) | 411 |
Nondeductible debt issuance expenses | 19 | 3,179 |
Impact of state rate changes | 16 | 917 |
Nondeductible expenses | 91 | 37 |
Adjustments to Brazil deferred balances | 0 | 15 |
Adjustments to U.S. deferred balances | 93 | 63 |
Income tax benefit | (176) | (1,304) |
HN [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Deferred Tax Liabilities | 1,300 | |
Federal [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss carryforwards | $ 10,000 | |
Federal [Member] | Minimum [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforwards, expiration dates | Dec. 31, 2018 | |
Federal [Member] | Maximum [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforwards, expiration dates | Dec. 31, 2035 | |
State [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss carryforwards | $ 13,600 | |
State [Member] | Minimum [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforwards, expiration dates | Dec. 31, 2016 | |
State [Member] | Maximum [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Operating loss carryforwards, expiration dates | Dec. 31, 2035 | |
Brazil [Member] | ||
Operating Loss Carryforwards [Line Items] | ||
Net operating loss carryforwards | $ 12,700 | |
Valuation allowance | $ 100 | $ 3,000 |
COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Millions |
12 Months Ended | |||||
---|---|---|---|---|---|---|
Mar. 24, 2016 |
Jan. 12, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Feb. 06, 2009 |
Aug. 28, 2008 |
|
Leases [Abstract] | ||||||
Remaining term of lease | 21 years | |||||
Future minimum payments under operating lease commitments [Abstract] | ||||||
2016 | $ 0.7 | |||||
2017 | 0.4 | |||||
2018 | 0.3 | |||||
2019 | 0.2 | |||||
2020 | 0.1 | |||||
Thereafter | 0.8 | |||||
Lease expense | 0.7 | $ 0.8 | ||||
Irgovel - Events of Default [Abstract] | ||||||
Minimum EBITDA triggering default status | 4.0 | |||||
Irgovel [Member] | Minimum [Member] | ||||||
Irgovel - Events of Default [Abstract] | ||||||
Minimum EBITDA triggering default status | 4.0 | |||||
Sellers [Member] | ||||||
Loss Contingencies [Line Items] | ||||||
Amount of second installment on purchase agreement being withheld | $ 1.0 | |||||
Amount held in escrow | 1.9 | $ 2.0 | ||||
Amount of escrow liability in accrued expenses | 1.9 | $ 1.9 | ||||
Pre-acquisition contingencies | 0.3 | |||||
Escrow balance available to settle remaining contingencies | $ 1.7 | |||||
Sellers [Member] | Subsequent Event [Member] | ||||||
Loss Contingencies [Line Items] | ||||||
Settlement amount | $ 1.9 | |||||
Amount of escrow released | $ 1.9 | |||||
Repayment of term note | $ 1.0 | |||||
Sellers [Member] | Nutra SA [Member] | Subsequent Event [Member] | ||||||
Loss Contingencies [Line Items] | ||||||
Percentage of escrow funds released used to reduce subsidiary ownership | 90.00% | |||||
Decrease in ownership percentage of subsidiary | 0.85% | |||||
Pending Litigation [Member] | Former Irgovel Stockholder David Resyng [Member] | ||||||
Loss Contingencies [Line Items] | ||||||
Damages sought by plaintiff | $ 3.0 |
RELATED PARTY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 12 Months Ended | |||||
---|---|---|---|---|---|---|---|
May. 30, 2014 |
Jan. 31, 2014 |
Dec. 31, 2015 |
Dec. 31, 2014 |
Dec. 31, 2013 |
Jan. 31, 2016 |
Jun. 30, 2014 |
|
Related Party Transaction [Line Items] | |||||||
Number of warrants issued to acquire shares of common stock (in shares) | 162,586 | 265,000 | |||||
Interest paid | $ 1,817 | $ 2,628 | |||||
Issue of shares of common stock (in shares) | 162,586 | ||||||
Loss on extinguishment of debt | $ (1,904) | $ (906) | |||||
HN [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Amount of outstanding shares purchased | $ 2,000 | ||||||
Amount payable through promissory note | 3,300 | ||||||
Conversion price (in dollars per share) | $ 6.00 | ||||||
Common Stock [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Issue of shares of common stock (in shares) | 2,786,781 | ||||||
Common shares issued on conversion of convertible promissory note (in shares) | 1,724,461 | ||||||
Convertible Promissory Note [Member] | HN [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Amount payable through promissory note | 3,300 | ||||||
Baruch Halpern [Member] | Warrants [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Warrants canceled during the period (in shares) | 231,397 | ||||||
Baruch Halpern [Member] | Warrants [Member] | Expirations May 2020 [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Number of warrants issued to acquire shares of common stock (in shares) | 119,366 | ||||||
Exercise price of warrants (in dollars per share) | $ 5.25 | ||||||
Baruch Halpern [Member] | Warrants [Member] | Expirations January 2021 [Member] | Subsequent Event [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Number of warrants issued to acquire shares of common stock (in shares) | 25,000 | ||||||
Exercise price of warrants (in dollars per share) | $ 5.25 | ||||||
Baruch Halpern [Member] | Common Stock [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Issue of shares of common stock (in shares) | 710,056 | ||||||
Baruch Halpern [Member] | Convertible Subordinated Debt [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Due to related parties | $ 2,600 | ||||||
Interest paid | 200 | $ 100 | |||||
Loss on extinguishment of debt | $ (700) | ||||||
Stated annual interest rate | 5.00% | ||||||
Baruch Halpern [Member] | Note Payable [Member] | Subsequent Event [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Due to related parties | $ 300 | ||||||
Stated annual interest rate | 11.75% | ||||||
W. John Short [Member] | Warrants [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Number of warrants issued to acquire shares of common stock (in shares) | 3,806 | ||||||
W. John Short [Member] | Warrants [Member] | Expirations May 2020 [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Number of warrants issued to acquire shares of common stock (in shares) | 2,446 | ||||||
Exercise price of warrants (in dollars per share) | $ 5.25 | ||||||
W. John Short [Member] | Common Stock [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Issue of shares of common stock (in shares) | 12,777 | ||||||
W. John Short [Member] | Convertible Subordinated Debt [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Due to related parties | $ 50 | ||||||
Stated annual interest rate | 5.00% | ||||||
W. John Short [Member] | Convertible Subordinated Debt [Member] | Maximum [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Interest paid | $ 10 | $ 10 | |||||
Mark McKnight [Member] | HN [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Common shares issued on conversion of convertible promissory note (in shares) | 225,925 | ||||||
Mark McKnight [Member] | Convertible Promissory Note [Member] | HN [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Amount of cash paid | 700 | ||||||
Principal amount promissory note | 1,400 | ||||||
Nicole McKnight [Member] | HN [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Common shares issued on conversion of convertible promissory note (in shares) | 225,925 | ||||||
Nicole McKnight [Member] | Convertible Promissory Note [Member] | HN [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Amount of cash paid | 700 | ||||||
Principal amount promissory note | 1,400 | ||||||
Nicole McKnight [Member] | Unsecured Promissory Note [Member] | HN [Member] | |||||||
Related Party Transaction [Line Items] | |||||||
Principal amount promissory note | $ 100 | ||||||
Stated annual interest rate | 5.00% |
SEGMENT INFORMATION (Details) $ in Thousands |
12 Months Ended | |||
---|---|---|---|---|
Dec. 31, 2015
USD ($)
Segment
|
Dec. 31, 2014
USD ($)
|
Jan. 02, 2014
USD ($)
|
Dec. 31, 2013
USD ($)
|
|
SEGMENT INFORMATION [Abstract] | ||||
Number of reportable segments | Segment | 2 | |||
Segment information identified and reconciliation of segment information to total consolidated information [Abstract] | ||||
Revenues | $ 39,896 | $ 40,108 | ||
Cost of goods sold | 31,826 | 35,639 | ||
Gross profit | 8,070 | 4,469 | ||
Depreciation and amortization (in selling, general and administrative) | (1,779) | (2,879) | ||
Other operating expense | (12,567) | (14,354) | ||
Loss from operations | (6,276) | (12,764) | ||
Net income (loss) attributable to RiceBran Technologies shareholders | (8,268) | (23,029) | ||
Interest expense | (3,101) | (10,334) | ||
Depreciation (in costs of goods sold) | (2,284) | (3,670) | ||
Purchases of property | 1,068 | 5,423 | ||
Segment information for selected balance sheet accounts [Abstract] | ||||
Property, net, end of period | 18,328 | 24,753 | ||
Goodwill, end of period | 3,258 | 4,431 | $ 790 | $ 4,139 |
Intangible assets, net, end of period | 1,225 | 2,740 | ||
Total assets, end of period | 33,635 | 45,913 | ||
Corporate [Member] | ||||
Segment information identified and reconciliation of segment information to total consolidated information [Abstract] | ||||
Revenues | 0 | 0 | ||
Cost of goods sold | 0 | 0 | ||
Gross profit | 0 | 0 | ||
Depreciation and amortization (in selling, general and administrative) | (79) | (52) | ||
Other operating expense | (4,892) | (5,941) | ||
Loss from operations | (4,971) | (5,993) | ||
Net income (loss) attributable to RiceBran Technologies shareholders | (6,948) | (16,825) | ||
Interest expense | (1,404) | (7,949) | ||
Depreciation (in costs of goods sold) | 0 | 0 | ||
Purchases of property | 94 | 152 | ||
Segment information for selected balance sheet accounts [Abstract] | ||||
Property, net, end of period | 418 | 135 | ||
Goodwill, end of period | 0 | 0 | ||
Intangible assets, net, end of period | 0 | 0 | ||
Total assets, end of period | 3,203 | 4,041 | ||
Operating Segments [Member] | USA [Member] | ||||
Segment information identified and reconciliation of segment information to total consolidated information [Abstract] | ||||
Revenues | 23,341 | 23,096 | ||
Cost of goods sold | 15,923 | 16,124 | ||
Gross profit | 7,418 | 6,972 | ||
Depreciation and amortization (in selling, general and administrative) | (1,569) | (2,137) | ||
Other operating expense | (4,288) | (4,133) | ||
Loss from operations | 1,561 | 702 | ||
Net income (loss) attributable to RiceBran Technologies shareholders | 1,561 | 702 | ||
Interest expense | 0 | 0 | ||
Depreciation (in costs of goods sold) | (890) | (1,022) | ||
Purchases of property | 474 | 2,251 | ||
Segment information for selected balance sheet accounts [Abstract] | ||||
Property, net, end of period | 8,408 | 9,360 | ||
Goodwill, end of period | 790 | 790 | ||
Intangible assets, net, end of period | 1,225 | 2,658 | ||
Total assets, end of period | 15,554 | 17,854 | ||
Operating Segments [Member] | Brazil [Member] | ||||
Segment information identified and reconciliation of segment information to total consolidated information [Abstract] | ||||
Revenues | 16,601 | 17,012 | ||
Cost of goods sold | 15,949 | 19,515 | ||
Gross profit | 652 | (2,503) | ||
Depreciation and amortization (in selling, general and administrative) | (131) | (690) | ||
Other operating expense | (3,387) | (4,280) | ||
Loss from operations | (2,866) | (7,473) | ||
Net income (loss) attributable to RiceBran Technologies shareholders | (2,881) | (6,906) | ||
Interest expense | (1,697) | (2,385) | ||
Depreciation (in costs of goods sold) | (1,394) | (2,648) | ||
Purchases of property | 500 | 3,020 | ||
Segment information for selected balance sheet accounts [Abstract] | ||||
Property, net, end of period | 9,502 | 15,258 | ||
Goodwill, end of period | 2,468 | 3,641 | ||
Intangible assets, net, end of period | 0 | 82 | ||
Total assets, end of period | 14,878 | 24,018 | ||
Intersegment [Member] | ||||
Segment information identified and reconciliation of segment information to total consolidated information [Abstract] | ||||
Revenues | (46) | 0 | ||
Cost of goods sold | (46) | 0 | ||
Gross profit | 0 | 0 | ||
Depreciation and amortization (in selling, general and administrative) | 0 | 0 | ||
Other operating expense | 0 | 0 | ||
Loss from operations | 0 | 0 | ||
Net income (loss) attributable to RiceBran Technologies shareholders | 0 | 0 | ||
Interest expense | 0 | 0 | ||
Depreciation (in costs of goods sold) | 0 | 0 | ||
Purchases of property | 0 | 0 | ||
Segment information for selected balance sheet accounts [Abstract] | ||||
Property, net, end of period | 0 | 0 | ||
Goodwill, end of period | 0 | 0 | ||
Intangible assets, net, end of period | 0 | 0 | ||
Total assets, end of period | $ 0 | $ 0 |
SEGMENT INFORMATION, Revenue by Geographic Area (Details) - USD ($) $ in Thousands |
12 Months Ended | |
---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Revenues from External Customers by Geographical Area [Line Items] | ||
Total revenues | $ 39,896 | $ 40,108 |
Reportable Geographic Segment [Member] | ||
Revenues from External Customers by Geographical Area [Line Items] | ||
Total revenues | 39,896 | 40,108 |
Reportable Geographic Segment [Member] | USA [Member] | ||
Revenues from External Customers by Geographical Area [Line Items] | ||
Total revenues | 21,978 | 21,381 |
Reportable Geographic Segment [Member] | Brazil [Member] | ||
Revenues from External Customers by Geographical Area [Line Items] | ||
Total revenues | 9,548 | 14,257 |
Reportable Geographic Segment [Member] | Other International [Member] | ||
Revenues from External Customers by Geographical Area [Line Items] | ||
Total revenues | $ 8,370 | $ 4,470 |
FAIR VALUE MEASUREMENT (Details) - USD ($) $ in Thousands |
12 Months Ended | |
---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Fair value of convertible debt lower than carrying value | $ 100 | |
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract] | ||
Total liabilities at fair value | 9,700 | |
Brazil [Member] | ||
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract] | ||
Total liabilities at fair value | 6,300 | |
Derivative Warrant Liability [Member] | Recurring [Member] | ||
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract] | ||
Total liabilities at fair value | $ (678) | $ (955) |
Derivative Warrant Liability [Member] | Recurring [Member] | Minimum [Member] | ||
Additional assumptions used to calculate fair value [Abstract] | ||
Risk-free interest rate | 0.90% | 0.10% |
Expected volatility | 71.00% | |
Derivative Warrant Liability [Member] | Recurring [Member] | Maximum [Member] | ||
Additional assumptions used to calculate fair value [Abstract] | ||
Risk-free interest rate | 1.20% | 1.00% |
Expected volatility | 89.00% | |
Derivative Warrant Liability [Member] | Recurring [Member] | Weighted Average [Member] | ||
Additional assumptions used to calculate fair value [Abstract] | ||
Risk-free interest rate | 1.10% | 0.70% |
Expected volatility | 78.00% | 95.00% |
Derivative Warrant Liability [Member] | Level 1 [Member] | Recurring [Member] | ||
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract] | ||
Total liabilities at fair value | $ 0 | $ 0 |
Derivative Warrant Liability [Member] | Level 2 [Member] | Recurring [Member] | ||
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract] | ||
Total liabilities at fair value | 0 | 0 |
Derivative Warrant Liability [Member] | Level 3 [Member] | Recurring [Member] | ||
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract] | ||
Total liabilities at fair value | $ (678) | $ (955) |
FAIR VALUE MEASUREMENT, Unobservable Input Reconciliation (Details) - Recurring [Member] - USD ($) $ in Thousands |
12 Months Ended | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
|||||||||
Changes in level 3 items measured at fair value on a recurring basis [Roll Forward] | ||||||||||
Fair Value as of Beginning of Period | $ (955) | $ (1,685) | ||||||||
Total Realized and Unrealized Gains (Losses) | [1] | 1,001 | (1,209) | |||||||
Issuance of New Instruments | (724) | (7,610) | ||||||||
Net Transfers (Into) Out of Level 3 | 0 | 9,549 | ||||||||
Fair Value, at End of Period | (678) | (955) | ||||||||
Change in Unrealized Gains (Losses) on Instruments Still Held | 0 | 546 | ||||||||
Derivative Warrant Liability [Member] | ||||||||||
Changes in level 3 items measured at fair value on a recurring basis [Roll Forward] | ||||||||||
Fair Value as of Beginning of Period | (955) | (1,685) | ||||||||
Total Realized and Unrealized Gains (Losses) | [1] | 1,001 | (1,151) | |||||||
Issuance of New Instruments | (724) | (7,021) | ||||||||
Net Transfers (Into) Out of Level 3 | 0 | 8,902 | [2] | |||||||
Fair Value, at End of Period | (678) | (955) | ||||||||
Change in Unrealized Gains (Losses) on Instruments Still Held | 0 | 546 | ||||||||
Derivative Conversion Liability [Member] | ||||||||||
Changes in level 3 items measured at fair value on a recurring basis [Roll Forward] | ||||||||||
Fair Value as of Beginning of Period | 0 | 0 | ||||||||
Total Realized and Unrealized Gains (Losses) | [1] | 0 | (58) | |||||||
Issuance of New Instruments | 0 | (589) | ||||||||
Net Transfers (Into) Out of Level 3 | 0 | 647 | [3] | |||||||
Fair Value, at End of Period | 0 | $ 0 | ||||||||
Change in Unrealized Gains (Losses) on Instruments Still Held | $ 0 | |||||||||
|
;4=) RT?IWG!Z
MAGF$ZR!8H[3Q2^K1.E1'"B6*?Z95Z+A.Z4^1S[3+A'PFY OA-HO&4Z-H\Y$[
M7I4&)V(''LYNM?%P$T2\,O'>K!\[:IHX>%4>JM7=; D8_"#R*2L0[8@BF)DA'1&?+=BFB\S2&D0I:]G1QBC ]73$GA] Q$5:
MT$8FP,DT:<(>[ANMS"E&(-K+!)B9)BT3)S*(7)*JSUFV/Q9M5"*XD!*@;CC#$W#NA9SQ^Z3Y:>F)E_-9
M_3ETZ]*?J($GQ?^PVG8N;()1#0T=N'U5XP^86@@)*\5-^*)J,%:)F8*1H!]Q
M9#*,8]S)THFV3D@G0KH0OB4A>#0*,;]32\M"JQ&9GOJSV^P=7'L1IXQ<-N/:
M#IHZ-%X6YS+=;0MR]D)7F$@\1LQF01"GOFJ1XC5Z&BUNT[?7]&U,N(WN#P^W
M!;)K@2P*9%.+V5J+$7.<,?EMDWS5))\$=O\QF3'W7TS(Q<$)T&VXGP95:I V
MGMNRNCR!QW!3R">\+'K:PB^J6R8-.BGKKD\XY48I"\X^NP5+K1X0KF8&2%7,161 37D2XE!FH5''7R"6?F/FXE)F"-*,[3 $\ %*.
MNO*(@.:#P>7.K)+C6[E?!Y/^42>18/X$S>]#\9K 0>ZWG;[* ("H3P8X7A,X
MU 058SP*>"PHOF,^&VM\<>=0.11:M6'N HA216+I4:4X7F(X=VU]Q\$#D-<*
MP?$"PV&OH)Q$XC-$>(GA8XEQ;&W7 .H.%@39[T7O#JNEK@_#S443;,VY:NUQ
M:&J=;D>^L/ZP>]/^0!=/%&E_IHN-O?MX<[]:GK*#_B>K#WG5!"^F[8[8PTEX
M;TRKNZ#)77?:/^IL-WT4>M_VKTGW7ML;$/O1FM-XH3/=*JW^!U!+ P04
M" (@WY((KGSW"X$ !@% &0 'AL+W=O